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Background: Lung and esophageal cancer rank among cancers associated with the 
highest mortality both in the United States and the World. Surgical intervention provides 
the best opportunity for cure for these cancers.   
Objectives: The objective was to identify factors associated with outcomes in surgical 
patients with thoracic cancers within a single hospital setting. We sought to achieve this 
goal with three aims, 1) examine the association between adjuvant chemotherapy and 
mortality among esophageal adenocarcinoma patients who received combined 
neoadjuvant chemoradiation therapy followed by surgery, 2) investigate differences by 
race on recommendation for surgery and survival among early stage non-small cell lung 
cancer (NSCLC) patients, and 3) determine the effect of HIV infection on post-surgical 
outcomes among NSCLC patients. 
Methods: Data from the Johns Hopkins Hospital Cancer Registry were used for the 
retrospective cohort study designs and analyses. The Kaplan-Meier method was used to 
illustrate time to postoperative events. To estimate associations with postoperative 
mortality we applied Cox proportional hazards regression models. Poisson regression 
with robust variance was used to estimate the prevalence ratio of surgical 
recommendation.  
Results: Aim 1: There was a long-term survival benefit following surgery for patients 
who received adjuvant chemotherapy compared to no adjuvant chemotherapy (median 
survival in months: 37.9 vs. 24.7; p=0.057, respectively). Receipt of adjuvant 
chemotherapy was associated with a 25% decrease in the aHR for postoperative mortality 
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compared to patients who did not receive adjuvant chemotherapy (0.75; 95% CI 0.55-
1.01).  
Aim 2: Black patients were 8% less likely to be recommended surgical resection as 
compared to white patients (crude RR=0.92, 95% CI 0.86-0.98), but this association 
became null after controlling for patient-, tumor-, and physician-related factors 
(aRR=0.99, 95% CI 0.93-1.05). There was no significant association between race and 
mortality (aHR=1.17, 95% CI 0.89-1.55). 
Aim 3: The median survival time for HIV-infected cancer patients was significantly 
shorter than for HIV-unspecified patients (26 vs. 48 months; p=0.001). Mortality among 
HIV-infected patients was more than threefold that of HIV-unspecified patients 
(aHR=3.08; 95% CI 1.85-5.13). When additional surgical characteristics were modeled in 
a matched sub-cohort, the association remained statistically significant (aHR=2.31; 95% 
CI 1.11-4.81).  
Conclusions: Adjuvant chemotherapy for patients with locally advanced esophageal 
adenocarcinoma was associated with reduced postoperative mortality compared to no 
adjuvant chemotherapy. Race was not independently associated with surgical 
recommendation or mortality for early stage NSCLC. After surgery, HIV-infected 
NSCLC patients have poorer survival than HIV-unspecified NSCLC patients. 
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 Cancers of the chest, specifically lung and esophagus have a grim prognosis. Even 
with improved diagnostic and imaging technologies the insidious nature of thoracic 
cancers often leads to the identification of advanced disease leaving patients and 
healthcare providers with fewer treatment options. To date, surgical resection of a 
localized tumor remains the optimal treatment option for a cure [1, 2].  
 Esophageal carcinoma is the most rapidly increasing solid organ tumor in the 
western world, and is invariably lethal with an overall 5-year survival of approximately 
17% in the 1990s [3]. With current neoadjuvant chemoradiation therapy the 5-year 
survival rate has almost doubled to 36-40% [4]. A subgroup of patients, about 30%, 
exhibit complete chemoradiation treatment response with no evidence of tumor in the 
esophageal specimen after surgery [5, 6]. This small subgroup of complete responders is 
typically associated with significantly improved 5-year survival of around 70% to 80% 
[5]. Lung cancer is the second most common and most lethal form of cancer in the U.S. 
[7]. The 5-year survival after stage I disease drops from 60% to less than 15% for stages 
II to IV combined [1].  
 A goal of the research described in this dissertation was to utilize clinical 
epidemiological methodology to identify factors associated with optimal surgical 
management and postoperative survival among patients diagnosed with thoracic cancer 
within a hospital setting. The first study aimed to identify clinicopathologic 
characteristics associated with post-operative survival following neoadjuvant 
chemoradiation among esophageal cancer patients. Aim 2 focused on potential racial 
disparities in the recommendation for surgical intervention as well as postoperative 
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survival among non-small cell lung cancer (NSCLC) patients. The third and final aims 
sought to examine differences in postoperative survival and time to recurrence by HIV 





Epidemiology of esophageal carcinoma 
 Esophageal cancer is the eighth most commonly diagnosed cancer, and the sixth 
most common cause of cancer death worldwide with a case fatality rate of 90% [7-9] 
illustrating that cancer of the esophagus remains a highly lethal disease. Developing 
nations account for more than 80% of the total cases and deaths [10]. Over the past thirty 
years, esophageal cancer incidence has steadily risen in the U.S.. The National Cancer 
Institute’s (NCI) Surveillance, Epidemiology, and End Results (SEER) Program reports 
that from 1975-2011 the annual rate of increase in incidence of esophageal cancer was 
0.5% [8]. The American Cancer Society (ACS) estimates that in 2014, 18,170 (14,660 in 
men and 3,510 in women) new cases of esophageal cancer will be diagnosed and 
approximately 15,450 (12,450 in men and 3,000 in women) patients will die from the 
disease, in the U.S. [7, 8]. Esophageal cancer is also included among a handful of cancers 
that are contributing to increasing death rates (20%) among males in the U.S. [11]. 
Despite these facts, esophageal cancer receives little attention when compared with other 
cancers such as lung, breast, prostate, and colorectal in terms of health promotion, 
education and prevention.  
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 Temporal trends in incidence vary for the two major histologic types of 
esophageal cancer – adenocarcinoma (EAC) and squamous cell carcinoma (SCC) [12, 
13] – each apparently having a distinct etiology [14]. Squamous cell carcinoma is the 
most common histological type worldwide, with a higher incidence in developing 
countries [15]. The epidemiology of esophageal cancer in the U.S. has dramatically 
changed over the past thirty years when squamous cell carcinoma was responsible for 
90% of the cases. Adenocarcinoma is now the leading histologic type of esophageal 
cancer in the U.S, representing 80% of incident cases [16]. In 1975 esophageal 
adenocarcinoma affected four people per million, in 2001 the rate had increased to 
twenty-three people per million. The National Cancer Institute (NCI) regards esophageal 
adenocarcinoma as one of the fastest-growing cancers in the U.S. [16]. Incidence rates for 
adenocarcinoma of the esophagus have been increasing in several Western countries, in 
part due to increases in known risk factors such as Barrett’s esophagus [17], 
gastroesophageal reflux disease [18], overweight and obesity [19]. In contrast, rates for 
squamous cell carcinoma have been steadily decreasing in these same Western countries 
because of long-term reductions in tobacco use and alcohol consumption [19, 20].   
 In the U.S., the rates and temporal trends of esophageal cancer differ by sex, race, 
and histologic type. According to a study using SEER data from 1977 to 2005, overall 
incidence rates for esophageal cancer among men were about triple of those among 
women. Incidence rates among black men and women (15.8 and 4.7 per 100,000 person-
years, respectively) were twice that of white men and women (7.1 and 2.0 per 100,000 
person-years, respectively). By histological type, blacks account for 87% of squamous 
cell carcinoma as compared to only 47% in whites. Black men have the highest incidence 
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rates for squamous cell carcinoma. The incidence rate for squamous cell carcinoma 
histology is four times higher in black versus white men (2.7 vs. 13.6 per 100,000 person-
years, respectively). Conversely, for adenocarcinoma histology, white males have the 
highest incidence rates. The rates for adenocarcinoma among white men are five times 
that among black men and women (3.7 vs. 0.8 and 0.2 per 100,000 person-years, 
respectively) [21].     
 
Esophageal cancer and survival 
 Esophageal carcinoma often has an insidious onset and, by the time of diagnosis, 
most patients are found to have significant nodal metastases with the average patient 
presenting with advanced stage disease [22]. The overall 5-year survival for disease 
localized to the esophagus (stage I) was reported to be 34%, while survival for all other 
stages (stage II-IV) is much lower at 17% [3]. Esophageal cancer treatment and prognosis 
is based on stage of disease, which is determined by endoscopic ultrasound (EUS) and 
histologic evalution of a biopsy specimen. Staging of esophageal cancer is categorized by 
TNM classification which determines how far the tumor has spread into the lining of the 
esophageus and/or other parts of the body [23]. The American Joint Committee on 
Cancer (AJCC) [24] recommends the TNM classification system to stratify extent of 
disease for esophageal cancer into five main categories, stages: 0, I, II, III, and IV (Figure 
1-1).  Sub-categories further divide each stage for tumor, lymph node, and metastatic 
involvement. Stage 0 is pre-cancer containing abnormal cells called high grade dysplasia, 
which requires further observation. Stage I is cancer that has grown into the deeper layers 
of the esophagus wall but has not reached the lymph nodes or other organs. Patients 
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diagnosed with stage I esophageal cancer are typically those whose cancer was incidently 
detected early and surgery (esophagectomy) to remove the part of the esophagus that 
contains the localized tumor is usually sufficient treatment. Stages II includes cancers 
that have grown into the main muscle layer of the esophagus or into the connective tissue 
on the outside of the esophagus, and also may include spread to 1 or 2 nearby lymph 
nodes (stage IIb). Stage III includes cancers that have grown through the wall of the 
esophagus to the outer layer as well as nearby organs tissues and lymph nodes. Stage IV 
is the most advanced stage, when the cancer has spread to distant organs and lymph 
nodes. Patients diagnosed with stages II to IV esophageal cancer are most often 
recommended chemoradiation followed by surgery [24, 25].   
 Historically, patients found with locally advanced disease (stages IB to IV) at 
time of surgery were treated with total or partial esophagectomy and lymph node 
dissection, and recommended for chemotherapy [26, 27]. Even after this therapy, the 
five-year survival ranged between 15% and 20% [28, 29]. Survival rates in metastatic 
esophageal cancer (stage IV) remain low, and outcomes in patients with locoregional 
(locally advanced, stages IB to IIIB) resectable esophageal cancer have slightly improved 
since incorporating neoadjuvant chemotherapy and radiation therapy combined with 
surgery (also referred to as “multimodality therapy” and will be used interchangeably 
throughout this report) in the treatment of this patient population. “Neoadjuvant therapy” 
is defined as treatment given as a first step to shrink a tumor before the definitive therapy 
is given, which is almost always surgery (surgery is the definitive treatment for 
esophageal cancer). Examples of neoadjuvant therapy (also sometimes referred to as 
induction therapy) include chemotherapy, radiation therapy, and hormone therapy, issued 
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either alone or in combination. Due to encouraging preliminary data in the late 1980s, 
some high-volume medical institutions began to use combined multimodality therapy in 
an effort to improve the long-term survival of patients with locally advanced esophageal 
cancer [2, 30-32].  
 
Therapeutic approaches to treatment and pathologic tumor response 
for esophageal cancer 
 Multimodality therapy comprising neoadjuvant chemotherapy and radiation 
therapy followed by radical resection, or otherwise known as esophagectomy surgery, is 
increasingly utilized in esophageal cancer and is now an accepted standard of care in the 
U.S. for patients with locoregional esophageal cancer [33]. A treatment course for a 
typical patient diagnosed with locally advanced esophageal cancer at Johns Hopkins 
Hospital is illustrated in Figure 1-2.  Although, esophagectomy remains the cornerstone 
treatment for esophageal cancer [34] the systemic nature, i.e. the high likelihood of 
microscopic residual disease leading to progression to metastatic esophageal cancer 
reduces the effectiveness of surgery alone. Numerous observational studies and clinical 
trials have attempted to address the optimal treatment sequence in managing locoregional 
esophageal cancer [3, 29, 30, 35-38]. Past data concerning short- and long-term patient 
outcomes of neoadjuvant chemoradiotherapy plus surgery have been inconclusive with 
respect to surgery alone. Several randomized trials have shown conflicting results 
comparing survival between multimodality therapy and surgery alone, but even without 
definitive data, neoadjuvant chemoradiation has become increasingly more common in 
clinical practice, especially at high-volume medical institutions, including the Johns 
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Hopkins Hospital, mainly due to the poor outcome associated with surgery alone [4, 30, 
33, 39]. 
 Over the span of 20 years, there have been 10 randomized trials comparing 
neoadjuvant chemoradiation followed by surgery with other modalities (mainly surgery 
alone as the control arm) [3, 6, 36, 37, 40-45]. The majority of esophageal cancer patients 
enrolled in these trials had squamous cell histology, which is less common in the U.S. 
compared to adenocarcinoma. The most recent trial, published in 2012, was a phase III 
study (the CROSS study) which randomized patients with locoregional resectable 
esophageal cancer to receive surgery alone or neoadjuvant chemotherapy with concurrent 
radiotherapy followed by surgery. Over two-thirds of the patients in this study had 
adenocarinoma histology. The median overall survival was 49.4 months in the 
neoadjuvant chemoradiation-surgery group versus 24.0 months in the surgery alone 
group. The neoadjuvant chemoradiation-surgery group showed a statistically significant 
reduced hazard ratio (HR) for post-operative mortality compared to the surgery alone 
group (0.66; 95% CI, 0.49 – 0.87) [6]. The results from this trial has been adopted as the 
guiding source for current treatment recommendations for patients with locally advanced 
esophageal cancer. It remains unclear whether survival and response to multimodiality 
therapy differs by histology, as such, clinical recommendations for therapy do not differ 
by histology at this time.   
 The CROSS study reported that 29% of patients who received neoadjuvant 
chemoradiation followed by surgery achieved a pathological complete response (pCR). A 
complete pathological response is defined as no evidence of disease found in the resected 
tumor specimen after administration of preoperative chemotherapy or radiation therapy. 
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The achievement of a complete pathological response or a major response is associated 
with an improved survival [32, 35, 46]. The attainment of a complete pathologic response 
to the neoadjuvant regimen is believed to be the best proxy measure of a successful 
outcome [47]. Studies have found a pCR can be achieved in 20%-30% of cases with 5-
year survival rates of approximately 70% irrespective of the applied treatment protocol, 
type of histology and tumor stage [5]. However, up to 70% of patients show an 
incomplete or no response to the neoadjuvant regimen, and the identification of factors 
that predict a response would be of considerable clinical benefit [47, 48]. 
 Currently, pathological response to mulitmodality therapy is the most informative 
prognostic marker for patients with locoregional esophageal cancer, regardless of stage or 
histological type [31, 32]. Analysis based on pathologic stratification not only yields 
important information about tumor biology but also gives insight into tumor chemo- and 
radiation sensitivity. Molecular research in understanding how the biology of esophageal 
tumors respond to therapy is an advancing area. Tumor markers of esophageal cancer are 
still in development stages of research but could potentially lead to advances in earlier 
diagnosis as well as playing a key role in assessing tumor response to systemic therapy.  
 
Adjuvant chemotherapy for esophageal cancer 
 Neoadjuvant chemoradiation followed by esophagectomy remains an essential 
component of treatment and can lead to improved overall survival compared to surgery 
alone, especially when performed at high-volume medical institutions. However, the role 
of adjuvant chemotherapy following multimodality therapy remains unclear. It has been 
shown that a complete pathological response to multimodality therapy can be achieved in 
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30% to 40% of esophageal cancer patients with locally advanced disease and has much 
better 5-year overall survival compared to pathological partial responders and no 
responders (52% vs. 36% vs. 22%, respectively) [6, 32, 49]. The degree of pathological 
response remains the most informative predictor of overall and disease-free survival in 
patients undergoing multimodality therapy. Yet, even among pathological complete 
responders the postoperative recurrence rate is about 10% to 15% and even higher 
recurrence rates among pathological partial responders and non-responders (20% to 35%) 
[32], demonstrating that pathological response is not a perfect predictor of disease-free 
prognosis. Residual disease among pathological partial- and non-responders and micro-
metastases among pathologic complete responders, not identified by current 
histopathological technology, likely play a role in disease progression and recurrence, 
respectively. 
 Only as recently as 2012 was the debate settled on how best to treat esophageal 
cancer patients with neoadjuvant therapy stemming from evidence from the CROSS 
study [6].  Adjuvant chemotherapy following multimodality therapy has now become a 
controversy. To date, there is no standard recommendation of care to guide clinicians on 
how or when to provide additional chemotherapy after surgery for esophageal cancer 
patients. No randomized trials have studied efficacy of adjuvant therapy followed by 
multimodality therapy for esophageal cancer.  Reasons against opting to treat 
patients with adjuvant chemotherapy include chemo-toxicity, patient fatigue, organ 
insufficiency, co-morbidities, post-operative complications, and mainly lack of data on 
the long-term clinical benefits or risks to the patient. Arguments for the use of additional 
chemotherapy following multimodality therapy address the systemic nature of esophageal 
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cancer and the poor prognosis associated with the disease even among patients that 
achieve a pathological response to neoadjuvant therapy. Proponents for adjuvant 
chemotherapy believe that patients who achieved a pathological partial response and are 
in good physical health after surgery should continue additional chemotherapy to treat 
their residual disease. Unfortunately, however, evidence supporting the clinical benefits 
of adjuvant chemotherapy is sparse, inconsistent, and largely anecdotal [32, 33].           
 
Lung Cancer 
Epidemiology of lung cancer 
 Since 1985, lung cancer has been the most common cancer worldwide [50]. 
Globally, lung cancer is the most commonly diagnosed cancer as well as the leading 
cause of cancer death in males and it is the fourth most commonly diagnosed cancer and 
second to breast cancer in deaths among women. Almost as many Americans die of lung 
cancer every year as die of prostate, breast, and colorectal cancers combined [51]. In 
2008, lung cancer was responsible for 1.6 million (13%) of the total cancer cases and 1.4 
million (18%) of cancer deaths, worldwide [52]. Lung cancer is the second most common 
malignant neoplasm for men and women in the U.S. and is responsible for more deaths 
than any other cancer [8, 9]. The American Cancer Society estimates for 2014 that about 
116,000 and 108,210 new lung cancer cases will be diagnosed for men and women, 
respectively [7]. In 2014, there will be approximately 159,260 (86,930 in men and 72,330 
among women) deaths from lung cancer, accounting for about 27% of all cancer deaths 
in the U.S. [7]. The 5-year survival rate in the U.S. for lung cancer is dismal (15.6%), and 
although there has been some improvement in survival during the past few decades, the 
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survival advances that have been realized in other common malignancies have yet to be 
achieved in lung cancer.  
 The majority of lung cancer is diagnosed in older persons with a median age at 
diagnosis of 71 years in the U.S. [53]. Approximately, 0.2% of lung cancers are 
diagnosed in patients between age 20 and 34 years; 1.5% (35 to 44 years); 8.8% (45 to 54 
years); 20.9% (55 to 64 years); 31.1% (65 to 74 years); 29% (75 to 84 years); and 8.3% 
(≥85 years) [53].   
 Lung cancer is a malignancy that arises from the cells of the respiratory 
epithelium and can be divided into two broad categories. Small cell lung cancer (SCLC) 
is a highly aggressive malignant tumor derived from cells with neuroendocrine histologic 
characteristics and accounts for 15% of lung cancer cases. The most common type, non-
small cell lung cancer (NSCLC), accounts for the 85% of cases. NSCLC can be further 
sub-divided into 3 major histologic subtypes- adenocarcinoma, squamous cell carcinoma, 
and large cell carcinoma. Adenocarcinoma accounts for 40% of all NSCLC cases, with 
squamous cell carcinoma and large cell accounting for 20% and 2.9%, respectively [54]. 
Adenocarcinoma has been increasing over the past 30 years and has surpassed squamous 
cell carcinoma as the most common type of NSCLC. The total (all stages) overall 5-year 
survival rate for lung cancer in the U.S. for 2001 to 2007 was 15.6%. Patients with 
localized disease at diagnosis have a 5-year survival rate of 52%; however, the more than 
52% of patients with distant metastasis at diagnosis have a 5-year survival rate of only 
3.6% [53, 54].   
 Cigarette smoking is unquestionably the most important preventable cause of lung 
cancer in the U.S. and worldwide [7]. Cigarette smoking accounts for at least 30% of all 
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cancer deaths in the U.S. and accounts for 87% and 70% of lung cancer deaths in men 
and women, respectively [1];with a relative risk of 20 to 25 and an attributable risk of 
85% to 90% [55]. Studies have shown reductions in risk for lung cancer after smoking 
cessation [56]: an 80% to 90% reduction in risk for lung cancer has been seen in smokers 
who have quit smoking for 10 to 15 years compared to persons who continue to smoke 
[57]. Other risk factors contributing to the risk of lung cancer include environmental 
tobacco smoke, occupational exposure to asbestos and radon, and diet [55].   
 Following the 1964 U.S Surgeon’s General Report that evidence was sufficient to 
conclude that cigarette smoking caused lung cancer, smoking prevalence for males began 
to decline, followed by women in the 1970’s [58]. Since the start of the U.S. lung cancer 
epidemic in the 1930’s, lung cancer has become the leading cause of cancer death in men 
[1]. The epidemic began in women with a sharp increase in mortality from lung cancer in 
the late 1960’s and has become one of the top two leading causes of death among women 
in the U.S [1, 59]. Although mortality rates of lung cancer for men began to decline in the 
1980’s, women are only now beginning to show a slight decline in lung cancer mortality 
[1, 7]. The incidence and mortality rates for lung cancer tend to mirror one another 
because most patients diagnosed with lung cancer eventually die of it. In men in the U.S., 
lung cancer death rates have decreased by 2% per year from 1994 to 2006 [51]. However, 
during the same period (1995 to 2005), lung cancer death rates in women continued to 
increase by 0.3% per year [51]. Far more men than women still die from lung cancer each 
year, but the gender gap in deaths from lung cancer is steadily narrowing [51]. This trend 
is due to historical differences in smoking patterns, with smoking prevalence having 
peaked approximately 20 years earlier among men than women [58, 60].  
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  Among cigarette smokers, the incidence of lung cancer is higher among blacks 
and Native Hawaiians and other Polynesians and lower among Japanese Americans and 
Hispanics compared to whites in the U.S. [61]. However, racial and ethnic differences 
seem to dissipate among individuals with heavy smoking (>30 cigarettes per day). Thus 
racial and ethnic differences in lung cancer rates have been initially attributed to 
variations in cigarette smoking patterns. Smoking prevalence in the U.S. is lowest among 
Asians (9.9%) and Hispanics (15.8%) and highest among American Indians and Alaska 
Natives (32.4%), whereas blacks and whites have similar rates 21.3% and 22%, 
respectively [62] even after adjusting for age [50]. However, only 8% of black smokers 
smoked at least 25 cigarettes per day compared to 28% of white smokers in the U.S. [62]. 
Nevertheless, differences in lung cancer rates by race remain. Black men are about 40% 
more likely to develop lung cancer than white men [62, 63]. The incidence rate is similar 
in black and white women and women also have lower rates than men but the gender gap 
has been closing [8, 64, 65].  
 
Disparities in surgical therapy for lung cancer 
 Although cigarette smoking has declined significantly over the past 50 years, 
disparities in tobacco use remain across groups by race, ethnicity, educational level, and 
socioeconomic status and also across regions of the U.S. Major advances have been made 
in the ability to image and identify lung tumors and metastases, diagnose and stage lung 
cancer with minimally invasive techniques, and safely resect early-stage lung cancers in 
patients. Despite such advances disparities in treatment and survival remain. A 
disproportionate number of cancer deaths occur among racial and ethnic minorities, 
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particularly African Americans, who have a 33% higher risk of dying of cancer than 
whites [66]. Although differences in incidence and stage of disease at diagnosis may 
contribute to racial disparities in mortality, inequalities in the receipt of cancer treatment 
may play an important role. Poor screening and prevention efforts, health care system and 
provider biases, and differences in patient socioeconomic and socio-cultural 
characteristics are thought to be prevailing factors underlying racial disparities.  
 A study using SEER data from 1988 through 1995 reported that among patients 
diagnosed with NSCLC, black patients less frequently received a recommendation for 
surgery than white patients [67]. Similarly, an analysis of Medicare data from 1985 
through 1989 showed lower surgical resection rates for local/regional stage non-small 
cell lung cancer and higher rates of no definitive treatment of distant-stage non-small cell 
lung cancer among black patients compared to white patients [68]. Pulmonary resection 
provides the best chance of cure for patients with early-stage disease [69-71]. Black 
patients with early-stage lung cancer have lower 5-year survival rates than white patients, 
and this difference in outcome has been attributed to lower rates of resection among black 
patients [64].  
 In a prospective study by Cykert et al, [72] the surgical resection rates for patients 
with tissue-confirmed non-small cell lung cancer of equal stage at diagnosis were 63% 
for blacks vs. 75% for whites, which was statistically significant (p=0.03). In a 
retrospective study using SEER data between 1985 and 1993, Bach et al, [71] also 
reported that blacks were significantly less likely to undergo surgical resection than 
whites for non-small cell lung cancer (64.0% vs. 76.7%; p<0.001, respectively). In 
addition, the 5-year survival was significantly lower for blacks, a finding associated with 
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the difference in resection rates [64, 71]. It has been shown that surgical treatment can 
[71] improve survival across race groups. Farjah et al, [73] found a difference in rate for 
surgical treatment between blacks and whites, however among those who did undergo 
surgery, blacks and whites postoperative survival were similar. Disparities in lung cancer 
care also have been found in other groups. Hispanic patients with stage I non-small cell 
lung cancer have lower rates of surgical resection and poorer survival as compared with 
white patients [74].  
 Barriers to the receipt of optimal cancer therapy are likely numerous and complex 
[75]. Several potential factors underlying racial differences in the receipt of surgical 
therapy include differences in pulmonary function [76], access to care [77], refusal of 
surgery [78], beliefs about tumor spread on air exposure at the time of operation [79] and 
the possibility of cure without surgery [80], distrust of the health care system and 
physicians [81], suboptimal patterns of patient and physician communication [82], and 
health care system and provider biases [73, 83, 84]. Differences in patient characteristics 
(i.e., lung function, performance status, and severity of comorbidities) and health care 
system and provider biases are often argued to be significant factors underlying racial 
disparities [72, 85].  
 
Epidemiology of HIV-associated non-small cell lung cancer 
 A number of epidemiologic studies have noted an elevated risk of lung cancer 
among HIV-infected individuals [86-93]. Since the introduction of highly active 
antiretroviral therapy (HAART), persons infected with human immunodeficiency virus 
(HIV) have been living longer, healthier lives [94]. Concomitantly, there has been a 
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decrease in AIDS-related malignancies such as Hodgkin lymphoma and Kaposi sarcoma 
[95] and an increase in the proportion of deaths attributable to non-AIDS-defining 
tumors, especially lung cancer [96, 97]. However, their risk of developing lung cancer 
seems to be much higher than that in the general population even after controlling for 
elevated rates of cigarette smoking in the HIV-infected population [98-101]. Lung cancer 
is the third most frequent cancer in persons with HIV infection, only after AIDS-defining 
malignancies of Kaposi sarcoma and non-Hodgkin lymphoma [88, 102]. In fact, lung 
cancer is the most common and most deadly non-AIDS-associated cancer in the HIV-
infected population, accounting for 16% of deaths in patients with HIV infection [103]. 
 While the higher risk of lung cancer in HIV-infected population compared to the 
general population of the same age seems to be due, in part, to the higher prevalence of 
smoking among HIV-infected patients, smoking does not appear to explain all of the 
excess risk with relative risks ranging between 2.0 and 4.0 after adjustment for smoking 
[99, 100]. Although smoking remains an important risk factor for the risk of lung cancer 
among HIV-infected persons, several other factors may contribute to the higher 
incidence. These include greater prevalence of co-infection with oncogenic viruses, such 
as human herpesvirus 8, human papillomavirus and Epstein-Barr virus. HIV-infected 
populations also have a higher prevalence of comorbidities that are associated with higher 
risk for lung cancer, including pneumonia and tuberculosis, which induce prolonged 
inflammation processes. Direct consequences of HIV could also play a potential role in 




Surgical intervention for HIV-infected non-small cell lung cancer 
 Typically, HIV-infected lung cancer patients present at a younger age, with more 
advanced stage of disease, and worse overall survival as compared to the general 
population [105, 106]. In fact, so advanced is the stage at presentation, that only 10-15% 
of HIV lung cancer patients have disease amenable to curative resection [106]. The 
median survival of lung cancer patients with HIV infection is only 3 to 6 months as 
compared to all patients with advanced staged lung cancer (10 to 12 months) [106-111]. 
The poor performance status of patients with HIV infection and lung cancer undermines 
their ability to tolerate surgery, chemotherapy, and radiation therapy [112]. HIV-infected 
lung cancer patients with in good general health, with higher CD4 counts and adherent to 
highly active antiretroviral therapy should have a survival advantage after cancer 
treatment [113, 114].  
 No single institution has accumulated a large experience with these patients, and 
to date, little is known about the clinical efficacy of surgical resection, when appropriate, 
in HIV-infected lung cancer patients. Due to the small number of patients presenting with 
early disease, only a few authors have reported on surgical outcomes in this patient 
population using very small numbers of case reports [96, 109, 112-119] with a 
cumulative total in the literature of fewer than twenty-five HIV-infected lung cancer 
patients who have undergone surgical resection. At present, the general consensus based 
on this limited set of cases has been for aggressive surgical resection in HIV-infected 





 The purpose of the studies featured in this dissertation was to apply a clinical 
epidemiological approach to examine key factors that play an important role in the 
treatment and survival of patients diagnosed with thoracic cancers. The Johns Hopkins 
Hospital Cancer Registry is the source population from which inferences are made on the 
target population, i.e., thoracic cancer patients treated in a hospital setting. Our 
conclusions based on adjuvant chemotherapy for patients diagnosed with locally 
advanced esophageal adenocarcinoma who received multimodality therapy will provide 
clinicians with information to make better treatment decisions. We expect that our work 
will further understanding of the complex relationship between disparities in race and 
surgical treatment and survival among early stage NSCLC patients and provide additional 
clinical insight on why candidates for surgery may refuse treatment. Finally, our results 
based on HIV-infected NSCLC patients who undergo surgery for curative intent will 
inform medical and public health collaborative programs on recommendations for best 
treatment practices for the unique set of challenges posed by this group of NSCLC 
patients. Ultimately, we hope our work provides future guidance in medical practice and 




 The specific aims and associated hypotheses of this dissertation are as follows: 
  
Aim 1. To examine the association between adjuvant therapy and postoperative mortality 
among locally advanced esophageal adenocarcinoma patients treated with combined 
neoadjuvant chemoradiation followed by surgery. 
 Using data from the Johns Hopkins Hospital Cancer Registry between 1989 and 
2011, we investigated the association between clinicopathologic prognostic 
characteristics of patients treated with and without adjuvant chemotherapy and time from 
surgery to death accounting for pathologic response to neoadjuvant therapy. 
 We hypothesized that patients diagnosed with locally advanced esophageal 
adenocarcinoma who received adjuvant chemotherapy would have improved survival 
compared to patients with similar clinicopathologic characteristics and pathologic 
response who received combined chemoradiation followed by surgery alone treated at 
Johns Hopkins Hospital between 1989 and 2011. 
 
Aim 2. To investigate differences by race on recommendation for surgical therapy and 
postoperative survival among early stage non-small cell lung cancer patients.  
 To better understand the relationship between race and recommendation for 
surgery, we conducted a retrospective cohort study using the Johns Hopkins Hospital 
Cancer Registry of patients enrolled from 2000 to 2010.  
 We hypothesized that there would be no racial disparities among patients with 
early-stage non-small cell lung cancer patients who received a recommendation for 
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surgery at Johns Hopkins Hospital between 2000 and 2010 after accounting for other 
patient-, tumor- and physician-related factors. We further hypothesized that overall 
survival would not differ by race once surgical recommendation was taken into account. 
 
Aim 3. To determine the effect of HIV infection on post-surgical outcomes among non-
small cell lung cancer patients.  
 Utilizing data from the Johns Hopkins Hospital Cancer Registry, we examined 
differences in clinical characteristics and all-cause, cancer-specific, and progression-free 
survival between HIV-infected and HIV-unspecified NSCLC patients who underwent 
surgery at Johns Hopkins Hospital from 1985 to 2010. A matched subcohort analysis 
further examined detailed intra- and post-operative differences between HIV-infected and 
HIV-unspecified NSCLC surgical patients. 
 We hypothesized that HIV-infected patients with NSCLC would have poorer 
postoperative survival compared to HIV-unspecified NSCLC patients with similar 
clinical risk factors who underwent surgery at Johns Hopkins Hospital from 1985 to 
2009. We further hypothesized that HIV-infected patients would have shorter time to 
disease progression as compared to HIV-unspecified patients with similar clinical risk 
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Background: Evidence informing current guidelines advising adjuvant chemotherapy 
subsequent to neoadjuvant chemoradiation therapy followed by surgery, also referred to 
as multimodality therapy, for esophageal cancer is limited. Our objective was to identify 
patients with locally advanced esophageal adenocarcinoma treated with multimodality 
therapy that may benefit from adjuvant chemotherapy.  
Methods: A single institution retrospective cohort study was performed in 308 patients 
with esophageal adenocarcinoma who underwent multimodality therapy between 1989 
and 2011. Kaplan-Meier analysis compared postoperative survival by clinical response to 
multimodality therapy and the use of adjuvant chemotherapy. Cox proportional hazards 
regression models estimated the association of adjuvant chemotherapy with postoperative 
mortality.  
Results: After multimodality treatment, 30% (93/308) received adjuvant chemotherapy. 
Partial response to multimodality treatment was observed in 150 (48%) patients; 50 of 
whom received adjuvant therapy. The median survival for partial responders who 
received adjuvant therapy vs. those receiving multimodality therapy alone was 53.2 vs. 
27.6 months, respectively (p=0.047). Patients with complete response or no response to 
multimodality therapy showed no difference in median survival with the addition of 
adjuvant chemotherapy.  Cox regression revealed a 25% decrease in relative hazard for 
long-term survival amongst patients who received adjuvant chemotherapy compared to 
no adjuvant therapy after adjusting for clinical response to multimodality therapy, age, 
and ASA score (aHR=0.75, 95% CI 0.55-1.01).  
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Conclusions: Adjuvant therapy for patients with locally advanced esophageal 
adenocarcinoma was associated with decrease in postoperative mortality compared to 
multimodality treatment alone, after adjusting for clinical response, age, and ASA. Partial 




 In the United States (U.S.), there was an estimated 17,990 new diagnoses of esophageal 
carcinomas and 15,210 deaths in 2013 [1]. Historically, before the advent of modern 
surgical, chemotherapeutic or radiotherapy modalities, mortality associated with 
esophageal carcinomas in the U.S. has been high, with an estimated overall survival of 
5% between 1975 and 1977. When surgical resection alone became the standard of care, 
cure rates improved in the range of 10-20% [2]. Nevertheless, the high rates of local and 
distant failure prompted increasingly aggressive perioperative treatments. While multiple 
clinical trials have individually demonstrated the efficacy of neoadjuvant therapies on 
patient survival, the optimal sequence of perioperative treatment remains to be 
elucidated.  
 In the current era of multidisciplinary treatment options, perioperative strategies 
have been estimated to improve survival for esophageal carcinoma by approximately 
15% compared to surgery alone [3]. A meta-analysis by Sjoquist which included 9 
randomized trials found a 13% decreased risk of all-cause mortality amongst patients 
with esophageal and gastroesophageal (GE) junction cancers who received preoperative 
chemotherapy vs. surgery alone (HR 0.87; 95% CI, 0.79-0.96, p<0.005) [4]. Notably, the 
CROSS Trial revealed that pre-operative carboplatin and paclitaxel in combination with 
radiotherapy improved overall survival (HR 0.657, p=0.003) [5].  
 At our institution, preoperative chemoradiotherapy became a treatment option for 
patients with esophageal carcinoma as early as 1989, and subsequently became the 
backbone element of perioperative, multimodality therapy. Importantly, adjuvant 
chemotherapy was never embraced. This was partly due to its poor tolerability by patients 
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after multimodality therapy, its theoretical disadvantages including postoperative removal 
of blood supply, and poor compliance with medication. Overall, there was no convincing 
evidence of the direction of the effect of adjuvant therapy after resected esophageal 
cancer.  
 Trials that have focused on adjuvant therapy have offered a mixed view. For 
resected gastroesophageal(GE) junction and gastric cancers, there is some evidence 
suggesting a slight benefit from the American Intergroup 116 trial in 2000, in which 
patients who received adjuvant chemoradiation with bolus 5-fluorouracil(FU)/ leucovorin 
had an increased relapse-free survival (RFS) and overall survival (OS) vs. observation 
alone (3-year OS 51% vs. 40%, p=0.005) [6]. The Japanese Adjuvant Chemotherapy 
Trial of TS-1 for Gastric Cancer study, using a mixture of tegafur, gimeracil and oteracil, 
found a significant improvement in RFS and OS (3-year OS 80.1% vs. 70.1%, p=0.003) 
[7]. In Europe, results from the phase III Medical Research Council Adjuvant Gastric 
Infusional Chemotherapy trial found that patients with gastric cancer who received 3 
cycles each of pre- and postoperative ECF (epirubicin/cisplatin/infusional 5-FU) and 
surgery resulted in significant increased 5-year OS compared to surgery alone (36% vs. 
23%, p=0.009) [8]. There is unfortunately however, a paucity of data focusing on 
outcomes following adjuvant chemotherapy after multimodality therapy for esophageal 
cancers. 
 Since there is so little evidence informing current guidelines advising on whether 
to use postoperative chemotherapy following multimodality therapy for esophageal 
adenocarcinoma, the 2013 National Comprehensive Cancer Network (NCCN) guidelines 
for adenocarcinoma only states that preoperative chemoradiation is the preferred primary 
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treatment for patients with resectable tumors (T1b, N+ and T2-T4a, N0-N+) and are 
medically fit for surgery [9]. All postoperative treatments recommendations are based on 
surgical margins. Our objective was to assess the long-term survival of patients with 
locally advanced esophageal adenocarcinoma treated with multimodality therapy and 
adjuvant chemotherapy. We hypothesized that patients who received adjuvant 
chemotherapy would have improved survival compared to patients with similar 





 The study cohort was comprised of patients with biopsy-proven esophageal 
adenocarcinoma and a documented assessment by a thoracic surgeon, medical oncologist, 
gastroenterologist, and radiation oncologist at the Sidney Kimmel Comprehensive Cancer 
Center at the Johns Hopkins Hospital (JHH) between May 1, 1989 and August 31, 2011 
from the JHH Cancer Registry. Patients were included if they underwent multimodality 
therapy, which was defined as receiving pretreatment clinical staging, neoadjuvant 
chemotherapy and radiotherapy and an esophagectomy with curative intent. 
 The JHH Cancer Registry collects data on all patients diagnosed with and/or 
treated for all cancers, including esophageal cancer, at JHH. Following national standards 
for data collection, coding, and staging, JHH certified tumor registrars collect data on 
incidences, primary site, histology, extent of disease, treatment, and outcomes. The JHH 
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Cancer Registry assures lifetime follow-up of cancer patients and assures that 96% have 
current information within the last 14 months.  
 
Data collection 
 Data were collected from the JHH Cancer Registry, and additional clinical data 
were abstracted from hospital records, electronic and paper files. Vital status was 
determined through December 31, 2012. In addition, to the JHH Cancer Registry’s active 
surveillance for vital status; patients who were identified as not being deceased by the 
JHH Cancer Registry were cross-validated using surgeons’ case logs and the Social 
Security Death Index. The Johns Hopkins University School of Medicine Institutional 
Review Board approved this study. 
 
Clinical Variables 
 Clinical variables included: smoking history, tumor site, neoadjuvant 
chemotherapy and radiation regimens, surgical procedure, ASA status, post-operative 
complications, clinical and pathological staging, and adjuvant chemotherapy regimens. 
Smoking history was self-reported as the number of packs smoked per day and total 
number of years smoked. Smoking status was categorized into no history or ever history 
of smoking. Tumor site was anatomically classified as the upper, middle, or lower third 
of the esophagus or the gastro-esophageal junction based on imaging and intra-operative 
findings. The American Society of Anesthesiologists 5-grade classification system was 
used as an index of preoperative comorbidities [10]. Post-operative complications were 
extracted from medical records, and patients were ultimately categorized as having any or 
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no post-operative complications. Pre-operative clinical staging was determined with the 
combinations of endoscopic ultrasound (EUS) first used in 1995, computed tomography, 
and positron emission tomography (PET) first used in 2000. Pathological stage was 
determined using the pathology record. Pathologic response to neoadjuvant 
chemoradiation was determined at the time of pathologic examination of the surgical 
specimen. 
 Pathologic response to neoadjuvant therapy was classified as complete response 
(pCR), partial response (pPR) and non-response (pNR). A patient was considered to have 
a complete pathologic response if no microscopic evidence of tumor was found upon 
examination of both the resected esophageal specimen and nodal tissues (T0N0M0). 
Partial response was defined as persistence of microscopic esophageal carcinoma in the 
resected surgical specimen but the pathological stage according to the American Joint 
Committee on Cancer (AJCC) was lower compared with the preoperative clinical stage. 
Non-response was defined as patients with no change in AJCC stage between clinical and 
pathologic staging, or progression of disease despite neoadjuvant therapy. 
 
Chemotherapy regimens 
 To investigate whether the type of adjuvant chemotherapy administered would 
deliver different outcomes, every patient’s perioperative chemotherapy course was 
classified as being the same or different. All 93 patients who received adjuvant therapy 
had known perioperative regimens. Neoadjuvant and adjuvant chemotherapy regimens 
were documented as the agents used prior to and following surgery, respectively. Each 
agent was classified under its primary mechanism of action. These included 
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antimetabolites, platinum-containing alkylating agents, taxanes, topoisomerase I and II 
inhibitors, EGFR inhibitors, VEGF inhibitors, and cytotoxic antibiotics. A patient’s 
adjuvant chemotherapy regimen was defined as being different from their neoadjuvant 
chemotherapy regimen if there was a minimum of one adjuvant agent with a different 
mechanism of action from any neoadjuvant agent. 
 
Statistical Analysis 
 Comparison of continuous, dichotomous, and categorical variables was performed 
using the nonparametric Wilcoxon rank sum test and x2 test for homogeneity, 
respectively. Time to all-cause mortality was examined using the Kaplan-Meier method, 
and survival differences were compared using the log rank test. Overall survival was 
defined as elapsed time from surgery date to death or the latest follow-up.  
 A Cox proportional hazards regression model was constructed to determine the 
association between adjuvant therapy and mortality. The model was adjusted by risk 
factors that included pathological response, age at diagnosis, and ASA performance 
status. Hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) are 
reported. Test based Schoenfeld residuals were used to confirm the proportional hazards 
assumption for the multivariable Cox regression model. All statistical tests were two-
sided and results were considered statistically significant for p values ≤0.05. All analyses 








Between June 1989 and July 2011, 308 patients underwent multimodality treatment for 
esophageal adenocarcinoma at our institution, of whom 93 (30%) received adjuvant 
chemotherapy. Clinicopathologic characteristics of the study population according to 
receipt of adjuvant chemotherapy are displayed in Table 2-1. Overall, the study consisted 
of mostly white men. Patients receiving adjuvant therapy were younger (median age, 57 
versus 62; p=0.023) and smoked fewer pack years (median pack years, 26 versus 32; 
p=0.025), compared to patients who did not receive adjuvant therapy.  There was no 
difference between median ASA scores between the two groups. Tumor was located in 
the lower third of the esophagus in 61% of patients. The majority of patients were 
clinically staged by PET with EUS; 81% within the adjuvant group and 78% within the 
no adjuvant group. Patients who did not receive adjuvant therapy experienced a slightly 
longer time interval between diagnosis and surgery by 6 days compared to those who did 
receive adjuvant chemotherapy. The surgical approach to esophageal resection was a 
transhiatal approach in the majority of patients; 85% and 83% in the adjuvant and no 
adjuvant groups, respectively. Patients who did not receive adjuvant therapy had a 
slightly increased median length of hospital stay by one day. Post-operatively, there was 
no significant difference between the proportions of patients who experienced 
complications following esophagectomy.  
 
Clinical and Pathological Staging 
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 The distribution of clinical and pathological stages according to receipt of 
adjuvant chemotherapy is presented in Table 2-2. The majority of patients presented 
initially at clinical stage cIII, without significant difference between the groups. 
Pathologically, the majority of patients in both groups were stage ypIIA, followed by 
those having no residual disease. Similar percentages of patients in both groups were 
complete responders, partial responders, and non-responders to neoadjuvant 
chemotherapy (p=0.393). 
 
Outcomes and survival 
 Using Kaplan-Meier estimates, there was a marginally statistically significant 
higher long-term survival following surgery for patients who received adjuvant 
chemotherapy. Median overall survival was 37.9 months for patients who received 
adjuvant chemotherapy and 24.7 months for patients who did not (p=0.057) (Figure 2-1). 
Stratified by clinical response, partial responders who received adjuvant therapy lived a 
median of 26 months longer than those who received multimodality therapy alone (Figure 
2-2). The median survival after adjuvant vs. no adjuvant therapy between complete 
responders or those who showed no response to neoadjuvant therapy was not statistically 
different (Figure 2-2).  
 Multivariable-adjusted hazard ratios were calculated to assess the association 
between adjuvant therapy and mortality, adjusting for clinical response, age at diagnosis, 
and ASA performance status (Table 2-3). Receipt of adjuvant chemotherapy was 
associated with a 25% decrease in relative hazards for postoperative mortality compared 
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to patients who did not receive adjuvant chemotherapy, which approached statistical 
significance (aHR=0.75; 95% CI 0.55 – 1.01; p=0.065). 
 
Comparing adjuvant regimens 
 The median number of adjuvant chemotherapy cycles received was 3 cycles. 
Median ECOG performance status was 0.5. There were a total of 14 Grade 3 and 5 Grade 
4 adverse events (Table 2-4). The most commonly delivered neoadjuvant chemotherapy 
regimen was cisplatin and 5-flurouracil. The most commonly delivered different adjuvant 
chemotherapy regimen was the addition of a taxol.  
 Forty-nine (53%) received the same regimen while the remaining 44 (47%) 
received different regimens. Among complete responders (20/93), there was no 
difference in proportion by who received the same or different regimens  (50% same vs. 
50% different). A larger percentage  received the same regimen within the partial 
responders group (50/93) (58% same vs. 42% different) while a larger 
percentagereceived a different regimen among those who did not respond to neoadjuvant 
therapy (23/90) (56% different vs. 43% same; p=0.495).  
 The comparison of median survival between patients receiving same or different 
adjuvant chemotherapy regimens stratified by clinical response is displayed in Table 2-5. 
There did not appear to be a difference in median survival for same vs. different 
chemotherapy regimens for complete, partial, or non-responders. Amongst partial 
responders, patients were further stratified by pathological nodal status into node negative 
or node positive (Table 2-5). Median survival was not yet reached for those with negative 
nodes who received the same adjuvant treatment. A longer median survival was observed 
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for patients with positive nodes who received different regimens compared to those who 
received the same regimen (53 vs. 18 months), though this difference was not statistically 
significant. Using Kaplan-Meier estimates, pathological node-negative partial responders 
who received the same adjuvant regimen appeared to have greater long-term survival 
compared to those who received a different regimen (Figure 2-3). Meanwhile, node-
positive partial responders appeared to have greater median survival if they received a 
different adjuvant regimen, however this difference was not found to be statistically 




This was a retrospective analysis of over 20 years experience at our institution of patients 
treated with multimodality therapy for esophageal adenocarcinoma. We found that partial 
responders to multimodality therapy who received adjuvant therapy lived a median of 26 
months longer than those who received multimodality therapy alone. Partial responders 
have distinct survival trajectories between recipients of adjuvant vs. no adjuvant therapy 
as early as one year post-operatively that persists up to ten years. Moreover, our data 
suggest that once you give a neoadjuvant chemotherapy regimen that provokes a 
response, more of that same chemotherapy given adjuvantly may improve survival 
benefit. For instance, we observed that partial responders, who responded so well to a 
certain neoadjuvant chemotherapy regimen that pathologically there was no evidence of 
malignancy in previously positive regional lymph nodes, demonstrated by a survival 
advantage when the same chemotherapy regimen was used adjuvantly. A plausible 
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explanation would be that the original tumor was sensitive to the initial regimen, and any 
remaining microscopic disease following surgical resection would similarly display 
susceptibility to the same regimen.  Of note, tests for interaction between mortality and 
pathologic response to multimodality therapy were not statistically significant. However, 
the authors decided that sub-group analyses were clinically relevant.    
 When partial responders did not respond well enough to pathologically clear their 
regional lymph nodes after the initial, neoadjuvant chemotherapy, changing the 
chemotherapy regimen in the adjuvant setting showed a trend towards longer survival. 
This  implies that malignant cells that were resistant to the initial regimen were 
specifically targeted by a different molecular mechanism. Although these results were not 
statistically significant, likely due to the small sample size of pathologic responders, they 
prompt the need for additional research on the effects of changing chemotherapy 
regimens following initial response. This rationale for using the same or different 
chemotherapeutic regimens both before and after surgery would be even better 
implemented as new molecular markers of chemosensitivity are brought to the clinic.   
 Based on Kaplan-Meier analysis, complete responders have the greatest long-term 
survival, with indistinguishable survival curves between those receiving adjuvant vs. no 
adjuvant. This may be expected, as patients with no residual disease would have no 
additional targets for adjuvant chemotherapy. Similarly, there does not appear to be a 
survival difference amongst patients who demonstrated no response to neoadjuvant 
therapy. The tumor biology that prevented resistance to initial therapy may explain why 
additional chemotherapy of the same mechanism provided no advantage. It is arguable 
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that patients who showed no response based on pathological staging may benefit from a 
different chemotherapy regimen postoperatively or alternative therapies where available. 
 While encouraging, the results of this study are limited by the retrospective 
methodology. Additionally, the side effects of perioperative chemoradiotherapy and its 
impact on patient quality of life and satisfaction were not considered. There may have 
been preferential selection for patients to undergo adjuvant chemotherapy given 
knowledge of clinical response to multimodality therapy. However, the distributions for 
receiving adjuvant therapy by clinical response was not statistically significantly different 
(p=0.393). It is also possible that the mechanism for decision to undergo adjuvant therapy 
may be more strongly related to patient health than pathologic complete response. 
Unfortunately, patient’s decision and reasons to accept or decline adjuvant therapy were 
not available. Finally, patients may have been enrolled in strict study protocols that 
precluded the option for adjuvant therapy or deviation from a chemotherapy regimen.  
 
Conclusions 
From our study, we conclude that adjuvant chemotherapy is advantageous in the 
multimodality approach for select patients with locally advanced esophageal 
adenocarcinoma. We found that outcomes following adjuvant therapy were dependent on 
clinical response to multimodality therapy. Specifically, partial responders were found to 
have longer overall median survival with adjuvant therapy vs. multimodality therapy 
alone. The results of this study may aid clinicians in deciding whether a patient with 
complete, partial, or no response to multimodality should receive additional adjuvant 
chemotherapy. Additionally, our preliminary results prompt the need for further 
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investigations into the possible advantages of altering adjuvant chemotherapy regimens 
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No Adjuvant Treatment              
215 (69.8%)  
  # % # % p value  
Median age at Diagnosis, years (IQR) 57 (52 - 64) 62 (51 - 69) 0.023 
Sex      
  Male 86 92.5 202 94.0 0.628 
  Female 7 7.5 13 6.0  
Race       
  White 90 96.8 208 96.7 0.989 
  Non-white 3 3.2 7 3.3  
Smoked Cigarettes      
  Never 16 17.2 39 18.1 0.844 
  Ever 77 82.8 176 81.9  
Pack-Years Smoked, median years (IQR) 26 (15 - 38) 32 (20 - 50) 0.025 
ASA      
  2 9 9.7 31 14.4 0.547 
  3 81 87.1 173 80.5  
  4 3 3.2 9 4.2  
  5 0 0.0 2 0.9  
Tumor Site      
  Upper Third 0 0 1 0.50 0.419 
  Middle Third 6 6.5 8 3.7  
  Lower Third 57 61.2 131 60.9  
  Distal 0 0.0 6 2.8  
  GE junction/Cardia 30 32.3 69 32.1  
Diagnostic Modality       
  CT only 1 1.1 31 14.4 <0.001 
  CT/EUS 17 18.3 17 7.9  
  PET/EUS 75 80.6 167 77.7  
Year of diagnosis      
  1988-1989 0 0 2 0.9 0.634 
  1990-1999 29 31.2 75 34.9  
  2000-2011 64 68.8 138 64.2  
Median days between diagnosis and surgery 111 (97-126) 117 (104-136) 0.035 
Transhiatal surgical approach 79 85% 179 83% 0.216 
Median length of hospital stay, days (IQR) 8 8-9 9 8-13 <0.001 
Post-operative complications 35 37.6 99 46.1 0.351 
 
IQR, interquartile range; ASA, American Society of Anesthesiologists; GE, gastroesophageal; CT, computed 







Table 2-2: Distribution of Clinical and Pathological Stages of Patients 




No Adjuvant Treatment              
215 (69.8%)  
 # % # % p value 
Clinical Stage       
  IIA 18 19.4 57 26.5 0.200 
  IIB 13 14.0 26 12.1  
  III 51 54.8 94 43.7  
  IV 11 11.8 38 17.7  
Pathologic Stage       
  No Evidence of Disease 20 21.5 61 28.4 0.263 
  I  12 12.9 32 14.9  
  IIA 26 28.0 67 31.1  
  IIB 15 16.1 17 7.9  
  III 16 17.2 32 14.9  
  IV 4 4.3 6 2.8  
Tumor Response to 
multimodality therapy      
  Complete response 20 21.5 61 28.4 0.393 
  Partial response 50 53.8 100 46.5  









Table 2-3: Multivariable-Adjusted Hazard Ratios (HRs) and 95% 
Confidence Intervals (CIs) Assessing the Association between 
Adjuvant Therapy and Mortality (N=308). 
  Adjusted HR 95% CI p value 
Adjuvant Chemotherapy    
  No 1.00 referent  
  Yes 0.75 (0.55 - 1.01) 0.065 
Age (years) 1.02 (1.00 - 1.03) 0.020 
ASA score 1.21 (0.86 - 1.69) 0.276 
Clinical Response    
  Complete response 1.00 referent  
  Partial response 1.65 (1.14 - 2.38) 0.008 
  No response 2.95 (1.97 - 4.41) <0.001 
 





Table 2-4: Median Number of Chemotherapy Cycles, Performance Status, and 
Number of Grade 3 and Grade 4 Events for Patients receiving Adjuvant 
Chemotherapy Following Multimodality Therapy. 
 
  Adjuvant Treatment 
(n=93) 
 No. of Subjects 
Median Chemo Cycles (IQR) 3 (1-5) 
ECOG Performance Status 0.5 
Adverse Events Grade 3 Grade 4 
  Neutropenia 1 3 
  Thrombocytopenia 2 0 
  Thromboembolic Disease 2 0 
  Deep Vein Thrombosis 3 0 
  Bacteremia/Sepsis 1 1 
  Heart Failure 1 0 
  Pulmonary Embolism 0 1 
  Renal Dysfunction/Failure 2 0 
  Hyponatremia 1 0 
  Osteoporosis 1 0 
 








Table 2-5: Comparison of Median Survival between Patients Receiving Same or Different 
Adjuvant Chemotherapy Regimens Stratified by Clinical Response and Pathological Nodal Status 
for Partial Responders Only. 
 Same Neoadjuvant and 
Adjuvant Treatment Regimens  
Different Neoadjuvant and 
Adjuvant Treatment Regimens 
 










Log rank  
p value 
Clinical Response      
  Complete response 53.7 (29.7 – NYR) 10 37.6 (9.3 – NYR) 10 0.716 
  Partial response 52.7 (17.2 – NYR) 29 53.2 (18.8 – 93.6) 21 0.220 
  No response 29.3 (19.5 – 36.6) 10 23.8 (17.3 – 36.8) 13 0.914 
Pathologic Nodal Status 
Amongst Partial 
Responders Only 
     
  ypN0 NYR (16.6 – NYR) 24 30.3 (18.1 – 93.6) 11 0.152 
  ypN1 18.0 (11.1 – 41.9) 4 53.2 (18.8 – 63.5) 10 0.266 
 
IQR, interquatile range; NYR, “Median Not Yet Reached”; ypN0 & ypN1, postoperative pathologic nodal status absence and 






Figure 2-1: Kaplan-Meier Estimates of Long-Term Survival Following Surgery for All 







Figure 2-2: Kaplan-Meier Estimates of Long-Term Survival Following Surgery for All 







Figure 2-3: Kaplan-Meier Estimates of Long-Term Survival Amongst Partial Responders 
Receiving the Same vs. Different Adjuvant Chemotherapy Regimens, Stratified by 
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Background: The current understanding on racial disparities in receipt of potentially 
curative surgical therapy involves a complex interplay of multifactorial mechanisms. 
Identifying differences in factors related to patient, provider, and disease characteristics 
along the diagnosis-treatment continuum may offer insight on how to mitigate disparities 
in clinical decisions for optimal therapy.  
Methods: A retrospective cohort study of patients in the Johns Hopkins Hospital Cancer 
Registry database who were diagnosed with stage I or II non-small cell lung cancer 
between 2000 and 2010 was conducted. Poisson regression with robust variance was used 
to estimate the prevalence ratio of surgical recommendation, which was reported as the 
relative risk (RR).  Cox proportional hazards regression models estimated the adjusted 
hazard ratios (aHR) for all cause mortality. 
Results: Among 904 white (81%) and black (19%) early-staged NSCLC patients, black 
patients were 8% less likely to be recommended surgical resection as compared to white 
patients (crude RR=0.92, 95% confidence interval [CI] 0.86 – 0.98). This association 
reduced to null after controlling for patient-, tumor-, physician-related factors (aRR=0.99, 
95% CI 0.93 – 1.05). There was no significant association between race and mortality 
(aHR=1.17, 95% CI 0.89 – 1.55). 
Conclusions: Race was not associated with surgical recommendation after adjusting for 
patient-, tumor-, and physician-related characteristics. Furthermore, race was not 
independently associated with mortality. Our study suggests recommendation for surgery 
differs by physician specialty and patient-physician encounter, yet these differences do 






Black patients with early-stage non-small cell lung cancer (NSCLC) have lower survival 
rates as compared to white patients, and this difference in outcome has been largely 
explained by the lower rates of surgical treatment among black patients [1, 2]. Lung 
cancer is the second most common malignancy and is the leading cause of cancer-related 
mortality in the U.S. [3]. Pulmonary surgical resection remains the primary and preferred 
approach to the treatment of stage I and II NSCLC [4, 5].  
 Several potential factors have been studied to better understand racial differences 
in the receipt of surgical treatment. Patient health-related factors that may be associated 
with racial differences in recommendation for surgical treatment include pulmonary lung 
function [6], co-morbidities [7], performance status, cigarette smoking [8], inadequate 
social support [2, 9], and access to care [10-13]. Also, patient belief patterns have been 
shown to effect the decision to undergo surgical treatment such as, beliefs about tumor 
spread on air exposure at the time of operation [14], and the possibility of cure without 
surgery, or simply refusal of surgery [15, 16]. Tumor-related factors such as advanced 
cancer stage at diagnosis and tumor histologic type help inform providers on therapeutic 
options such as surgery or systemic therapy [17, 18]. Finally, health care system and 
provider-related factors such as poor patient-provider communication such as discordant 
patient-provider race [19-22], distrust of the physician or healthcare system [22-24], and 
health care system and provider biases [24, 25] are often argued to be significant factors 
underlying racial disparities.    
 To better understand the factors influencing the recommendation for surgery 
including patient race, we conducted a retrospective cohort study. We hypothesized that 
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there would be no racial disparities among patients with early-stage NSCLC who 
received a surgical recommendation. We further hypothesized that overall survival would 




A study population of 904 patients treated for early stage (IA-IIB), non-small cell lung 
cancer (NSCLC) at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 
between January 1, 2000 and December 31, 2010 comprised the study cohort. 
Information on vital status and treatment was collected through May 31, 2012. Johns 
Hopkins Hospital (JHH) Cancer Registry personnel abstracted the medical record of 
patients treated in accordance with American College of Surgeon Guidelines.  
 The JHH Cancer Registry collects data on all patients diagnosed with and/or 
treated for lung cancer at JHH. Following national standards for data collection, coding, 
and staging, certified JHH tumor registrars collect data on incidences, primary site, 
histology, extent of disease, treatment, and outcomes. The JHH Cancer Registry assures 
lifetime follow-up of cancer patients and assures that 96% have current information 
within the last 14 months. The Johns Hopkins University School of Medicine 
Institutional Review Board approved this study. Information about patient-, tumor-, 
physician-related factors recommendation for surgical treatment and overall survival was 





 Personal factors were provided in the JHH Cancer Registry record. Patient-related 
factors included race (white/black), age (continuous, <65, 65-74, and ≥75 years), gender 
(male or female), marital status (married or not married), smoking history (current, 
former, never, or unknown), health insurance at the time of diagnosis (yes/no), and 
Census tract median household income, which was obtained from the U.S. Census 
Bureau 2000 estimates. Patients were identified as having co-morbidities if they had one 
or more of the following co-morbidities defined by International Classification of 
Diseases, 9th Revision; [401.0 - 405.9 (hypertensive disease); 410.0 – 414.9 (Ischemic 
Heart Disease); 415.0 – 417.99 (diseases of pulmonary circulation); 420.0 – 429.9 (other 
forms of heart disease); 430.0 – 438.9 (cerebrovascular disease); 440.0 – 448.9 (diseases 
of arteries, arterioles, and capillaries); 451.0 – 459.9 (diseases of veins and circulatory 




 Histological site (SEER) and stage were classified according to established 
American College of Surgeon conventions. Tumor characteristics included, year of 
diagnosis (2003 – 2009), histology (adenocarcinoma, squamous cell, bronchioalveolar 
carcinoma (BAC), adenosquamous, and non-small cell histology, not otherwise specified 
(NSCLC, not otherwise specified), stage (IA, IB, IIA, or IIB), surgical procedure 
(lobectomy, pneumonectomy, wedge resection, and segmentectomy). All surgical 





 Physician-specific factors collected were surgery recommending doctor’s race, 
sex and sub-specialty (surgeon, oncologist, and pulmonologist).   
 
Outcome  
 Surgical recommendation by initial surgery recommending physician was 
identified in the JHH Cancer Registry and confirmed by an audit of the patient’s 
electronic records. Surgical recommendation was defined as recommended for surgery or 
not recommended for surgery by the initial surgery recommending physician. If the initial 
surgery recommending physician’s sub-specialty was not surgery and did not recommend 
surgery, further patient chart review determined whether a surgeon was consequently 
consulted. While not included as an element of the definition for the outcome of surgical 
recommendation, patient refusal for surgical treatment was collected from the JHH 
Cancer Registry to provide further information on whether surgeons were consulted 
regarding the non-surgeon’s decision  not to recommend surgery. Reasons for not 
recommending surgery were collected and classified as “not part of the planned 1st course 
treatment”, “contraindicated”, “non-surgical procedure performed”, or “unresectable”.   
 
Statistical Analysis 
 Comparison of means and medians of continuous variables was performed using 
the student t test (two-sided) and nonparametric Mann-Whitney U test, respectively. 
Comparisons between proportions for binary and categorical variables were performed 
using the chi-squared test for homogeneity. Fisher’s Exact test was used to compare 
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differences in proportions when expected numbers in any cell were less than 5 units. All 
hypothesis tests were two-sided and results were considered statistically significant for p 
values ≤0.05. 
We assessed univariate and multivariable associations between physician 
recommendation for surgery, defined as either surgery recommended or surgery not 
recommended with Poisson regression with robust variance to estimate the prevalence 
ratio. Poisson regression with robust variance was selected as the best statistical model 
because the proportion with surgical recommendation was greater than 10% [26]. We 
tested for interactions of selected covariates with race; of specific interest were median 
household income, co-morbidity, and physician sub-specialty. Poisson regression results 
were reported as relative risks (RR) with 95% confidence intervals (CIs).  
Survival and the association of covariates were assessed using the Kaplan-Meier 
method and time to death was analyzed using the Cox proportional hazards model 
adjusted for multiple covariates. Survival was calculated from time of diagnosis to death 
or last follow-up. Differences in survival between groups were assessed using the log 
rank test. Cox regression results were reported as hazard ratios (HR) with 95% 
confidence intervals (CIs). Test based Schoenfeld residuals were used to confirm the 
proportional hazards assumption for the multivariable Cox regression model.  All 
regression model analyses were performed using the STATA 10.0 statistical software 





A total of 904 NSCLC patients with stages IA to IIB were identified between years 2000 
to 2010 and 19% were black race. Both race groups had similar gender distributions. 
Compared to whites, there was greater proportion of black patients who at time of 
diagnosis were age 65 or younger, not married, in the lowest quartile for median 
household income by Census tract, were current smokers, having histology other than 
adenocarcinoma, and had an initial consult with a non-surgeon. There were no 
statistically significant differences by race on distribution of tumor stage, surgical 
procedure, insurance coverage, or physician race (Table 3-1).  
 Black patients were recommended surgical resection less frequently than whites 
(84.3% vs. 91.7%, respectively, with an absolute difference of 7.4% less; p<0.003). In 
univariate analysis, black patients were 8% less likely to be recommended surgical 
resection as compared to white patients, which was statistically significant (RR=0.92, 
95% confidence interval [CI] 0.86 – 0.98; Table 3-2). After controlling only for patient-
related factors, the likelihood of recommendation for blacks remained stable but not 
statistically significant (aRR=0.95, 95% CI 0.88 – 1.02). While controlling only for 
tumor-related factors the likelihood for recommendation for surgery for blacks was 
reflective of the univariate model (aRR=0.92, 95% CI 0.86 – 0.99). After accounting for 
only physician-related factors, the association with race and recommendation was 
comparable with patient-related model (aRR=0.97, 95% CI 0.92 – 1.03). After fitting 
patient- , tumor-, and physician-related factors into the fully adjusted model there was no 
association of race and recommendation for surgery (aRR=0.99, 95% CI 0.93 – 1.05). In 
the physician-related and fully adjusted model, non-surgeons were significantly 
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negatively associated with surgical recommendation as compared to surgeons (aRR=0.47, 
95% CI 0.38 – 0.58).  
  Figure 3-1 shows overall survival after diagnosis by race and recommendation for 
surgery. Among patients recommended for surgery, black patients have poorer overall 
survival compared to white patients. The unadjusted medians and 5-year survival rates 
after diagnosis for whites compared to blacks was 6.07 years; 5-year 56% versus 4.28; 5-
year 44%, respectively (log rank test p=0.032). Interestingly, the opposite was observed 
among patients not recommended for surgery (test for interaction, p=0.108). However, 
the difference in survival was not statistically significant. Among cases not recommended 
surgery, black patients had improved survival after diagnosis (median years 2.12; 5-year 
22%) as compared to white patients (median years 1.03; 5-years 20%; log rank p=0.185).     
 The unadjusted HR for all cause mortality among black patients was elevated by 
26% as compared to white patients with marginal statistical significance (HR=1.26, 95% 
CI 0.99 – 1.60; Table 3-3). After adjusting for physician recommendation, patient- and 
tumor-related characteristics, the race association was attenuated (aHR=1.17, 95% CI 
0.89 – 1.55), while recommendation for surgery remained stable in the mortality hazard 
model (aRR=0.38, 95% CI 0.28 – 0.51).  
 Table 3-4 describes the distribution of characteristics among those patients who 
were not recommended surgery according to race, and consequently showed no 
differences by race. Of the 88 patients not recommended for surgery, 31% were black. 
Comparing proportions in whites versus blacks, reasons why patients were not 
recommended surgery included, 1) not part of planned 1st course treatment (46% vs. 
22%), 2) contraindication (31% vs. 48%), 3) non-surgical procedure was performed 
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(13% vs. 22%), and 4) tumor was deemed to be unresectable (10% vs. 7%). Blacks 
patients tended to have more co-morbidities than whites (70% vs. 57%; p=0.248), 
respectively. The majority of both patient groups were seen by a non-white physician, 
61% for whites and 74% in blacks (p=0.224). There were no differences in distribution 
by race for referring physician sub-specialty.    
 Among non-surgeons who were the initial referring physician (n=104), Table 3-5 
shows the proportion by race if a surgeon was consulted regarding the recommendation 
for or against surgery. There was no difference by race in the proportion of surgeons 
consulted when a non-surgeon did not recommend surgery (p=0.777) and no patient went 
on to get surgery if not recommended whether or not the surgeon was consulted. 
Although there was a difference in proportion of surgery consults by race among non-
surgeons that recommended surgery, those patients that did not subsequently consult a 




This study reported the association between patient’s race and likelihood of surgical 
recommendation after accounting for patient-, tumor-, and physician-related factors, and 
overall survival after adjustment for both recommendation and race among early stage 
NSCLC patients. In this study black patients were recommended for surgery 8% less than 
white patients, but after accounting for patient-, tumor-, and physician-related factors the 
association was reduced to approaching null.  After accounting for recommendation for 
surgery, patient- and tumor-related factors, the HR for all cause mortality for black race 
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was attenuated to aHR=1.17 and lost statistical significance. There were no 
characteristics disproportionate by race when not recommended surgery and surgeons 
tended to concur with treatment recommendations of non-surgeons. Race as a risk factor 
alone was not independently associated with surgical recommendation or overall 
survival. Our analysis suggests that patient-, tumor- and physician-related factors have a 
greater influence in the treatment recommendation process than racial characteristics 
alone.  
 Findings from this investigation suggest that consultation for surgical treatment at 
our institution was equally accessible regardless of patient race. Table 3-4 showed no 
differences by race among patients not recommended for surgery on factors influential on 
physician recommendation. Additionally, as shown in Table 3-5, patients whose initial 
physician encounter was with a non-surgeon, the recommendation not to have surgery 
was subsequently followed-up by a surgeon consult and was comparable by race. 
Furthermore, patients who were recommended for surgery but did not subsequently 
consult a surgeon ultimately decided to forego surgery. The reason for a patient not 
undergoing surgery was not within the scope of this investigation however those reasons 
are of great clinical interest and concern.   
 Some studies that examined racial disparities in receipt of lung cancer surgery 
among those recommended for surgery have found patient refusal rates higher among 
black patients than white patients [16, 24]. They proposed factors such as distrust of the 
healthcare team, cultural beliefs, and limited access to subspecialty care as substantial 
reason for refusal. Although receipt of surgery was not the aim of our investigation, we 
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also observed a marginal elevated refusal rate for surgery in blacks (11/19) 58% 
compared to whites (8/19) 42%.  
 Reasons for patient refusal for surgery may be personal decisions guided by 
numerous and complex issues, directly or indirectly associated with their socioeconomic 
environment. Sub-analysis found that 19 patients refused surgical treatment after the 
physician recommendation for surgery. Among these patients, 68% (13/19) were in the 
lowest tertile of median household income by Census tract ($8,365 - $36,045), and all of 
these patients resided in Baltimore City while the other 6 patients lived in distant counties 
with median household income by Census tract ranging between $43,031 and $107,735. 
Patient refusal for surgery in our study might be explained by financial stressors and loss 
of work or income during the surgical procedure and recovery process. In addition, 79% 
(15/19) were not married, which may have also influenced patient refusal for surgery 
given the lack of supportive home care and even the lack of supplementary financial 
support, usually provided by a spouse.       
 It has been proposed that black patients may tend to present with more severe 
comorbidities than white patients thereby precluding them from surgical recommendation 
[27]. We found no differences in proportion of having one or more comorbidities by race. 
However, prevalence of comorbidities was a significant independent covariate with an 
8% reduced probability for recommendation and the association remained stable even 
after adjustment for other patient-, tumor-, and physician-related factors (Table 3-2). 
However, after adjustment, prevalence of comorbidities was not a significant risk factor 
for overall survival in our study which we suggest that the severity of the comorbidities 
do not differ between white and black patients. The relative severity of having a co-
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morbidity may not have outweighed the risk compared to the outcome of not undergoing 
lung cancer surgery [7]. Current smoking was associated with increased HR for mortality 
(aHR=1.53 95% CI 1.00 – 2.35). It is possible that more severe co-morbidities, such as 
chronic obstructive pulmonary disease and poor pulmonary function are also associated 
with heavy smoking-related behaviors thereby precluding some patients from surgical 
recommendation.     
 Another finding from our investigation showed married individuals have a greater 
probability for surgical recommendation and have better survival compared to non-
married individuals, independent of other patient, tumor and physician-related factors. 
Our finding is not novel. Pruuthi et al, studied patients undergoing cystectomy for 
bladder cancer and found married individuals had improved perioperative, and 
postoperative survival outcomes compared to unmarried patients[28]. The benefits of 
marriage underscore the dynamic of healthy behaviors and actions that can effect timely 
and positive clinical decisions when reinforced by positive social support. 
 A sub-analysis revealed reasons why patients were not recommended for surgery. 
While the distributions did not differ statistically significantly by race, reasons include 
‘surgery was not part of the planned first course’ for the majority of whites while the 
majority of black patients had recorded ‘contraindication’ as the reason why not 
recommended. These reasons might indicate more patients with stage closer to IIB where 
neoadjuvant radiation is often recommended. Twenty-eight percent of patients not 
recommended for surgery were stage IIBcompared to 14% of patients recommended for 
surgery. Perhaps these patients have more severe comorbidities possibly related to heavy, 
long-term cigarette smoking. An alternative consideration as a reason why surgery was 
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not recommended among this group might be due to the increasing use of new and 
effective non-surgical procedures, such as dose-intensified conformal radiation therapy 
and radiofrequency ablation [29].   
 The majority of black patients in our study resided in Baltimore City (64%), while 
a minority of white patients resided in Baltimore City (11%). It may be that patients from 
other residential areas who were referred to Hopkins have better access to care and came 
to Hopkins with the intention of surgery. Whereas Baltimore City residents might not 
have had a similar system of care that facilitate medical examinations to identify cancer 
in a timely manner. However, we did collect information on insurance, median household 
income by Census tract, co-morbidities, and stage of disease. Only stage and the presence 
of one or more co-morbidities were statistically associated with surgical 
recommendation. We were not able to definitively assess whether a patient was first 
diagnosed at our institution or referred to our institution after initial diagnostic 
assessment. There might be patient or cultural characteristics about those who reside in 
Baltimore City that differ from those who were referred to our institution for care which 
may limit generalizability.   
 Recommendation of surgery may vary how it is measured because 
recommendation is “defined” by sub-specialties differently. This was a concern to the 
investigators since different sub-specialties have different clinical perspectives. We were 
able to collect information on the specialty of physician as surgeon, oncologist, or 
pulmonologist. Physician specialty was accounted for in the regression for surgical 
recommendation. Compared to surgeons, pulmonologists and oncologists were 
significantly less likely to provide a recommendation for surgery, a finding that remained 
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statistically significant after adjustment of patient-, tumor- and physician-related factors. 
Given the distribution of physician specialty varied by patient race, institutions should 
more closely evaluate how black and white patients enter into initial specialty encounters.   
 Physician recommendation is not independent of the patient preferences and 
input. Physicians do take patient opinion into account before making a recommendation. 
It could be that a patient might not have felt comfortable with surgery as an option and 
opted for non-surgical procedure and hence the observed a recommendation of “no 
surgery”.  Another limitation might be how the recommendation for surgery was 
measured that caused potential residual confounding. 
 A statistical strength of this study was the use of statistical models that directly 
measured the prevalence ratio of surgical recommendation by race. Unlike several prior 
studies that utilized logistic regression to model the relationship between race and receipt 
of surgical treatment, our study modeled the association between race and surgical 
recommendation as prevalence ratios using Poisson regression with robust variance given 
that the prevalence of recommendation in our study population was 90%. The odds ratio 
from logistic regression would have over-estimated the relative risk and log-binomial 
regression often has convergence issues [26].  In addition, we were able to examine 
physician recommendation for surgery separate from receipt of surgery, which makes this 






To summarize, after accounting for patient-, tumor-, and physician-related factors race 
was not independently associated with physician recommendation for surgery or survival. 
Recommendation and receipt of definitive surgery is strongly associated with greater 
survival. Given the nature of the clinical setting, findings from this study may not be 
widely generalizable beyond high volume medical institution settings similar to that of 
Johns Hopkins Hospital. However, our results may aid clinicians in identifying patients 
that are medically eligible for curative surgery but are at most risk to refuse surgical 
treatment due to socioeconomic disadvantages. More prospective clinical cohort studies 
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Table 3-1. Characteristics of the Study Population by Race, Johns Hopkins Hospital. 
(N=904) 
 





 172 (19.0%)  
Characteristics # % 
 
  # % 
p 
value* 
Sex       0.859 
  Male 352 48.1   84 48.8  
  Female 380 51.9   88 51.2  
Median Age, years & IQR 68 61-75   64 57-71 <0.001 
Age, years       0.003 
  <65 278 38.0   88 51.2  
   65 – 74 263 35.9   55 32.0  
   ≥75 191 26.1   29 16.8  
Married       <0.001 
  Not Married 246 33.6   105 61.1  
  Married 486 66.4   67 38.9  
Insurance Coverage       0.098 
  No 10 1.4   6 3.5  
  Yes 722 98.6   166 96.5  
Median Household Income,  
2000 US Census Tract (Quartiles)   
 
   <0.001 
  Q1 $7,944 - $34,922 117 16.3   105 62.5  
  Q2 $34,943 - $47,759 194 27.0   30 17.9  
  Q3 $47,778 - $65,156 199 27.7   21 12.5  
  Q4 $65,278 - $177,098 209 29.1   12 7.1  
Co-Morbidities       0.759 
  None 418 57.1   96 55.8  
  1 or more 314 42.9   76 44.2  
Smoking Status       0.001 
  Never 71 9.7   11 6.4  
  Former 435 59.4   82 47.7  
  Current 226 30.9   79 46.0  
Histology       0.008 
  Adenocarcinoma 357 48.8   79 45.9  
  Squamous cell 194 26.5   56 32.6  
  Large cell 16 2.2   6 3.5  
  BAC 104 14.2   9 5.2  
  NSCLC, nos 51 7.0   17 9.9  
  Adenosquamous 10 1.3   5 2.9  
Stage       0.114 
  IA 331 45.2   79 45.9  
  IB 249 34.0   54 31.4  
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  IIA 47 6.5   5 2.9  
  IIB 105 14.3   34 19.8  
Surgical Procedure       0.732 
  Lobectomy 545 82.2   112 83.6  
  Pneumonectomy 22 3.3   2 1.5  
  Wedge Resection 66 10.0   14 10.4  
  Segmentectomy 30 4.5   6 4.5  
Surgery Recommending  
Physician Specialty   
 
    
  Surgeon 663 90.6   137 79.6 <0.001 
  Oncologist 41 5.6   17 9.9  
  Pulmonologist 28 3.8   18 10.5  
Surgery Recommending  
Physician Race   
 
   0.063 
  White 211 28.8   62 36.1  
  Non-White 521 71.2   110 63.9  
 
* Nonparametric Mann-Whitney U test and Χ2 test for homogeneity 










Table 3-3. Crude and Adjusted Hazard Ratios and 95% Confidence Intervals (CI) Assessing the 
Association Between Race and Mortality Among Early Stage Non-Small Cell Lung Cancer 
Patients. (N=904) 
  
Crude    
Hazard 
Ratio 95% CI p value 
Adjusted 
Hazard 




     Caucasian 1.00 referent   1.00 referent 
   African-American 1.26 (0.99 - 1.60) 0.058 1.17 (0.89 - 1.55) 0.259 




     Male 1.00 referent   1.00 referent 




     Not Married 1.00 referent   1.00 referent 
   Married 0.75 (0.61 - 0.91) 0.003 0.78 (0.63 - 0.97) 0.026 




     Q1 ($7,944 - $34,922) 1.00 referent   1.00 referent 
   Q2 ($34,943 - $47,759) 1.07 (0.82 - 1.39) 0.632 1.20 (0.90 - 1.60) 0.222 
  Q3 ($47,778 - $65,156) 0.95 (0.72 - 1.25) 0.695 1.22 (0.90 - 1.65) 0.203 




     None 1.00 referent   1.00 referent 




     Never 1.00 referent   1.00 referent 
   Former 1.44 (0.97 - 2.15) 0.071 1.27 (0.84 - 1.91) 0.254 




     Adenocarincoma 1.00 referent   1.00 referent 
   Squamous cell 1.38 (1.10 - 1.73) 0.006 0.97 (0.76 - 1.24) 0.822 




     IA 1.00 referent   1.00 referent 
   IB 1.53 (1.22 - 1.92) <0.001 1.49 (1.18 - 1.88) 0.001 
  IIA 1.34 (0.83 - 2.16) 0.232 1.37 (0.84 - 2.22) 0.203 
  IIB 2.91 (2.24 - 3.78) <0.001 2.93 (2.23 - 3.85) <0.001 
Recommended for Surgery 
  
  
     Not Recommended 1.00 referent   1.00 referent 
   Recommended 0.32 (0.25 - 0.43) <0.001 0.38 (0.28 - 0.51) <0.001 
 
* Other histology- large cell, bronchioloalveolar adenocarcinoma (BAC), NSCLC, nos, and adenosquamous 
† Adjusted for recommendation for surgery, race, age at diagnosis, sex, marital status, median household income, 






Table 3-4. Distribution of Characteristics for Patients Not Recommended by Race. (N=88) 
 
White                   
61 (69.3%)  
 Black 
 27 (30.7%)  
 # %    # % p value 
Reasons Why Not Recommended       0.143** 
   Not part of the planned 1st course 28 45.9   6 22.2  
   Contraindicated 19 31.2   13 48.2  
   Non-surgical procedure performed 8 13.1   6 22.2  
   Tumor unresectable 6 9.8   2 7.4  
Stage       0.415** 
   IA 17 27.9   7 25.9  
   IB 24 39.3   10 37.0  
   IIA 5 8.2   0 0.0  
   IIB 15 24.6   10 37.0  
Married 30 49.2   10 37.0 0.291* 
1 or more co-morbidities 35 57.4   19 70.4 0.248* 
Smoking status       0.150** 
   Never 7 11.4   0 0.0  
   Former 34 55.7   15 55.6  
   Current 20 32.8   12 44.4  
Surgery Recommending  
Physician’s Race    
 
  0.224* 
   White 24 39.3   7 25.9  
   Non-White 37 60.7   20 74.1  
Surgery Recommending  
Physician’s Specialty     
 
  0.483* 
   Surgeon 22 36.1   8 29.6  
   Pulmonologist 19 31.2   12 44.4  
   Oncologist 20 32.8   7 25.9  
 
* Fishers Exact 









Recommended Surgery*  
(n=46) 
  Non-Surgeon  




White                   
30 (65.2%)  
Black 
 16 (34.8%) 
  White                   
39 (67.2%)  
Black 
 19 (32.8%) 
 













Surgeon consulted about  
non-surgeon recommendation      
 
0.001 
       
0.777 
   No 3 10.0  9 56.2   32 82.1  15 79.0  
   Yes 27 90.0  7 43.8   7 17.9  4 21.0  




     
 
   No surgeon consult  3 60.0  9 90.0         
   Surgeon consult 2 40.0  1 10.0         
 
* Of those recommended surgery and surgeon did not concur, all patients refused further treatment thus surgery consult never occurred.  
































Figure 3-1: Overall Survival of Early Stage Non-Small Cell Lung Cancer Patients by 






















Figure 1. Overall Survival of Early Stage Non-Small Cell Lung Cancer tatients
.y Race and Surgical Recommendation (N=904)
Key Median Survival in Years 
Recommended/White           6.07    
Recommended/.lack             4.28    
Not Recommended/.lack     2.12    
Not Recommended/White   1.03     
Global Log Rank p value <0.001
Recommended 
.lack vs. White
Log Rank p value = 0.032
Not Recommended 
.lack vs. White
Log Rank p value = 0.185
Recommended vs. 
Not Recommended 
Log Rank p value = <0.001
Rec/W 671 (100)              555 (89)               444 (78)                346 (71)               259 (63)               190 (56) 
Rec/. 145 (100)               116 (90)                 82 (74)                  62 (60)                 49 (55)               31 (44)
No Rec/. 27 (100)                 19 (77)                 11 (54)                     7 (34)                   4 (30)                3 (22)
No Rec/W 61 (100)                 30 (53)                 15 (35)                    9 (25)                    6 (20)                 4 (20)
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Background: To assess the effect of HIV-infection on post-operative survival among 
non-small cell lung cancer (NSCLC) patients. 
Methods: A retrospective cohort study compared 22 HIV-infected lung cancer patients to 
2,430 lung cancer patients with HIV-unspecified status resected at Johns Hopkins 
Hospital between 1985-2009. Sub-cohort comparative analyses were performed using 
individual matching methods.  
Results: Thirty day mortality rates did not differ between HIV-infected and HIV-
unspecified patients. Long-term survival rates in HIV-infected lung cancer patients were 
significantly shorter than in HIV-unspecified patients (median 26 vs. 48 months; 
p=0.001). After adjustment, the HR of mortality among HIV-infected NSCLC patients 
was ≥3 fold that of HIV- unspecified patients (aHR=3.08, 95% CI 1.85-5.13). When 
additional surgical characteristics were modeled in a matched sub-cohort, the association 
remained statistically significant (aHR=2.31, 95% CI 1.11-4.81). Moreover, HIV-infected 
lung cancer patients with CD4 counts <200 cells/mm3 had shortened median survival than 
those with CD4 ≥200 cells/mm3 (8 vs. 40 months; p=0.031). Postoperative pulmonary 
and infectious complications were also elevated in the HIV-infected group (p=0.001 and 
<0.001, respectively). After surgery, median time to cancer progression was shorter 
among HIV-infected patients (20.4 months) versus HIV-unspecified patients (p=0.061).  
Conclusions: Although surgery in HIV-infected NSCLC patients has comparable 30-day 
mortality to HIV-unspecified NSCLC patients, it is associated with more postoperative 
complications, more rapid progression to disease recurrence and poorer long-term 
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survival. Optimizing immune status prior to surgery and careful patient selection based 





Numerous epidemiologic studies have noted an elevated risk of lung cancer among HIV-
infected individuals [1-5]. Typically, these patients are younger, have advanced disease 
stage, and worse overall survival compared to the general population [6-8]. In fact, so 
advanced is their stage at presentation, that only 10-15% of HIV lung cancer patients can 
undergo curative resection [7]. No single institution has accumulated a large experience 
with these patients, and to date, little is known about the clinical efficacy of surgical 
resection in HIV-infected non-small cell lung cancer (NSCLC) patients. Due to the small 
number of patients with early disease, only a few authors have reported on surgical 
outcomes in this patient population [9-18] with a cumulative total in the literature fewer 
than 25 patients. The present general consensus based on this limited sample size has 
been to offer surgery with curative intent to HIV-infected NSCLC patients, regardless of 
their immune state, if there is localized disease and good patient performance status [9, 
16].   
Despite few HIV surgical patients with NSCLC in the literature, as a single 
institution, we have resected 22 HIV-infected NSCLC patients. We performed a 
retrospective cohort study to examine differences in characteristics and survival between 
HIV-infected and HIV-unspecified NSCLC patients who underwent surgery for curative 
intent at Johns Hopkins Hospital from 1985 to 2009.  
 





 The HIV infection status of 10,122 lung cancer patients treated between January 
1, 1975 and December 31, 2009, was determined by cross-referencing the Johns Hopkins 
HIV specialty clinic and the Johns Hopkins Hospital Cancer Registry. Consequently, 124 
HIV-infected patients with lung cancer were identified. Since the first HIV-infected lung 
cancer patient at Johns Hopkins was diagnosed on August 15, 1985, 2,162 patients 
diagnosed prior to 1985 were excluded. Any cancer types other than NSCLC were 
excluded, which subsequently removed 914 patients; 10 of whom were HIV-infected 
patients. Of the remaining 7,033 NSCLC patients, 4,581 (65%) received no surgical 
intervention, of which 92 were HIV-infected. The final study population comprises 2,452 
NSCLC patients who underwent surgery for curative intent, of which 22 were HIV-
infected. Johns Hopkins Institutional Review Board approved this study. 
 
Exposure of Interest 
 HIV infection was defined as being HIV-serostatus positive in the Johns Hopkins 
HIV specialty clinic database prior to pathologic confirmed diagnosis of NSCLC. Persons 
with NSCLC who were not identified as HIV-serostatus positive after cross-referencing 
the Johns Hopkins HIV specialty clinic and the SPORE Lung Cancer database were 
classified as HIV-unspecified.    
 
Exposure Assessment   
 Demographic characteristics, NSCLC subtypes, cancer staging, oncologic 
treatment, American Anesthesiology Classification morbidity index, HIV/AIDS-related 
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information, and associated risk factors were obtained from the Johns Hopkins SPORE 
lung cancer database, clinical charts, and the institution’s tumor registry using 
standardized collection forms and quality controlled data entry procedures. Surgical 
procedures for curative intent were defined as lobectomy, bilobectomy, or 
pneumonectomy. Sublobar resections were considered curative only when the surgeon 
documented this intent. 
 
Outcome Ascertainment 
 The primary end point was postoperative survival. Study entry was defined as 
date of surgery. Patients were followed until date of death, lost to follow-up, or 
administratively censored five years after resection. Vital status was confirmed with 
clinical records, death certificates, and the Social Security Death Index. The secondary 
end point was disease progression after surgery.  
 
Individual Matching 
 Since HIV-infected lung cancer patients are younger compared to the general 
population [19] and other clinical characteristics related to survival can be 
disproportionately distributed by HIV status, such as cancer stage, histology, race, sex, 
NSCLC diagnosis prior to and after HAART era, and even socioeconomic status [7, 8, 
16, 19, 20], we attempted to achieve “balance” on the distribution of observed factors that 
might potentially bias the effect of HIV on survival [21]. Therefore, a representative sub-
cohort was drawn from the surgical cohort; 3 HIV-unspecified surgical patients were 
individually matched to each HIV-infected surgical patient by age at NSCLC diagnosis, 
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sex, race, stage, NSCLC histologic subtype, date of surgery (+/- 5 years), and surgical 
procedure.   
 
Statistical Analysis 
 Comparison of means and medians of continuous variables was performed using 
the Student’s t-test (two-sided) and nonparametric Mann-Whitney U test, respectively. 
Comparisons between proportions for binary and categorical variables were performed 
using the χ2 test for homogeneity or Fisher’s exact test. All hypotheses tests were two-
sided, and results were considered statistically significant for p values <0.05. 
Survival was illustrated using the Kaplan-Meier method, and the association of 
covariates with time to death was analyzed using the Cox proportional hazards regression 
model. In the multivariable models, covariate adjustment for the larger (unmatched) 
surgical cohort was ultimately determined by differences in HIV status on observed 
characteristics within the entire cohort, prior belief, as well as clinical and biological 
plausibility. The individual matched sub-cohort analysis included all the covariates in the 
unmatched regression model, postoperative complications, and matched covariates. 
Results of Cox regression are reported as hazard ratios (HR) with 95% confidence 
intervals (CIs).   
 Covariates used for matching methods remained in the multivariable model to 
account for residual confounding. A test on the basis of Schoenfeld residuals confirmed 
the proportional hazards assumption for the matched sub-cohort multivariable Cox 
regression model (p=0.993). Stage presented in the regression models was treated as a 
continuous variable when tested for trend.  
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 A post-hoc sensitivity analysis was conducted to account for potential bias related 
to secular changes in overall survival due to the introduction of HAART.  We restricted 
our analytic cohort to only patients diagnosed with lung cancer during HAART (≥1996). 




Our NSCLC cohort consisted of 7,033 patients of which 114 HIV-infected NSCLC 
patients were identified. Among the HIV-infected individuals, 19% (22/114) underwent 
surgery for curative intent versus 35% (2,430/6,919) of HIV-unspecified individuals. In 
contrast to the HIV-unspecified patients, HIV-infected patients were significantly 
younger, African-American, and male (Table 4-1). Both groups were typical of a surgical 
cohort, each with a similar stage of disease with stage I predominating. In both groups, a 
lobectomy was the preferred procedure, and most patients had adenocarcinoma. Likely 
due to younger age, HIV-infected patients smoked fewer pack-years compared to HIV-
unspecified patients, 43 versus 54 pack-years, respectively (p=0.012). HIV-infected 
patients were more likely to have had a longer delay from diagnosis to surgery.  
 
Entire Cohort (Unmatched) 
 The 30-day mortality among HIV-infected and HIV-unspecified patients in the 
large analytic set did not differ and was 0% and 2.3%, respectively (Table 4-1). The post-
surgical median survival for HIV-infected patients was shorter at 26.4 months vs. 48.4 
months for HIV-unspecified patients (p=0.001; Figure 4-1). HIV-infection alone 
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conveyed a HR of long-term mortality of more than twice that of HIV-unspecified 
patients (unadjusted hazard ratio = 2.24, 95% CI 1.37-3.68; Table 4-2). After adjusting 
for risk factors related to overall survival among surgical patients into the multivariable 
Cox regression model, the relative hazard of mortality in the HIV-infected group 
increased and remained statistically significant (adjusted HR (aHR) =3.08, 95% CI 1.85-
5.13; Table 4-2). 
 
Matched Sub-Cohort  
 Characteristics of the individual-matched sub-cohort analysis according to HIV 
infection status are presented in Table 4-3a. Fifty-three percent of HIV-unspecified 
individuals were married compared to only 18% of HIV-infected individuals (p=0.004). 
In the HIV-unspecified group, the median household income was slightly higher 
($32,458 vs. $28,945, p=0.14). Both HIV-infected and HIV-unspecified individuals 
reside mainly within Baltimore City, 68% and 55%, respectively (p=0.26).  
 The median duration from diagnosis to surgery was greater for HIV-infected 
patients than HIV-unspecified individuals (72 vs. 40 days; p=0.02; Table 4-3b). HIV-
infected patients also experienced longer hospital stays (9 vs. 5 days; p=0.03); a likely 
consequence of more post-operative complications. Nearly half of HIV-infected patients 
experienced ≥2 complications compared to HIV-unspecified patients (46% vs. 9%, 
p<0.001). There were no statistical differences between mean percent predicted forced 
vital capacity or mean percent predicted forced expiratory volume in one second. 
Although, mean percent predicted diffusion lung capacity for carbon monoxide (DLCO) 
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differed by HIV status, data were available on only 55% (12/22) of HIV-infected and 
65% (43/66) of HIV-unspecified patients.  
 There was no difference between HIV-infected and HIV-unspecified groups 
among those who received adjuvant therapy (Table 4-3b). Seventy-six percent of patients 
with stage II or greater had progressive disease. Patients with stage I compared to stage II 
or greater experienced similar post-operative complication rates (data not shown). 
Importantly, thirty day mortality did not differ between HIV-infected and HIV-
unspecified patients (Table 4-3b). Finally, the number of lung cancer-related deaths did 
not differ between the HIV-infected and HIV-unspecified groups (Table 4-3b). 
 Individual-matched modeling estimated the adjusted hazard ratios between HIV-
infection status and postoperative mortality (Table 4-4). Matched on age, sex, race, 
histology, stage, surgical procedure, and surgical date, the crude relative hazard of 
mortality in the HIV-infected patients was increased by 81% compared to HIV-
unspecified patients (crude HR=1.81, 95% CI 1.02-3.25;p=0.047).  In the adjusted model, 
HIV-infected patients were associated with a significantly higher hazard of mortality 
relative to HIV-unspecified patients (aHR=2.31; 95% CI 1.11-4.81; p=0.026). Having ≥2 
complications was associated with an adjusted relative hazard of mortality almost 4 times 
greater than fewer complications (aHR=3.85; 95% CI 1.39-10.68; p=0.009). The cancer-
specific survival of the 22 HIV-infected surgical patients differed significantly by CD4 
cell count (Figure 4-2). Survival was significantly shorter among individuals with CD4 
cell counts below 200 cells/mm3 (median survival 8.3 vs. 40.0 months; p=0.031). Of the 
6 patients with CD4 count <200 cells/mm3, five died. Four patients died from their lung 
cancer, and one patient from AIDS-related causes. Four of the six patients with CD4 
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counts <200 also had cancer progression after surgery. Additionally, median time after 
surgery to cancer progression was shorter among HIV-infected compared to HIV-
unspecified patients (20.4 months vs. not yet reaching 50th percentile, p=0.061). Figure 4-
3 describes cumulative probability of cancer progression between HIV-infected and HIV-
unspecified surgical patients.  
 The associations persisted and remained statistically significant in all sensitivity 




Compared to HIV-unspecified NSCLC patients, HIV-infected NSCLC patients displayed 
grim postoperative survival rates. Overall and progression-free survival are equally 
dismal among HIV-infected patients. Even after adjustment for important clinical 
prognostic indicators, HIV-infected patients exhibited greater mortality.  Among HIV-
infected patients, immunosuppression at surgery correlates with rapid decline in survival. 
This finding runs contrary to prior recommendations advocating surgery for HIV-infected 
NSCLC patients regardless of immune status [16]. 
 Given the strong relationship between extent of disease and survival, it was 
expected that stage would account for the majority of variance in the model and attenuate 
the crude hazard ratio of HIV-infected status [7, 22]. However, this was not the case. 
Instead, after matching and conditioning on stage, the estimate of HIV infection effect 
increased, indicating that even with similar NSCLC stage, HIV-infected individuals have 
significantly poorer survival after surgery. To account for stage migration over the 
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study’s 20 years, the surgical year was included in our regression models and matched 
study design. Nonetheless, the impact of HIV on long-term survival in either the entire 
analytic population or in the matched sub-cohort analysis remained significant. 
  Compared to HIV-unspecified patients, HIV-infected individuals underwent 
surgery a month later after diagnosis. We can only speculate that this difference is 
indicative of potential barriers to medical care access commonly associated with HIV-
infected populations, including low income, lack of medical insurance, HIV-related 
comorbidities, drug abuse, and even transient residence [23]. Nevertheless, any delay in 
surgery had no detrimental effect on survival in HIV patients on multivariable analysis. 
 We show differences in survival between HIV patients by CD4 cell count, 
corroborating Thurer et al. who found in 4 HIV-positive NSCLC surgical patients, long-
term survival in the sole patient with CD4 lymphocytes >200 cells/mm3 [11]. This value 
is not completely arbitrary since constitutional symptoms begin in HIV patients with CD4 
counts <300 cells/mm3, serious opportunistic infections occur at CD4 counts <100 
cells/mm3,[11] and from 1992 to 2006 , the Center for Disease Control defined AIDS as 
CD4 cell counts < 200 cells/mm3 [24]. In this study, the CD4 cell count was measured as 
a fixed variable at the closest time prior to surgery. CD4 count can vary markedly within 
an individual, especially when patients are non-compliant with antiretroviral regimens 
[25]. Multiple measures of CD4 cell counts or of the nadir CD4 cell counts could reveal 
persistently low values that may better characterize immunosuppression. 
 In our study, HIV-infected patients were significantly more likely to develop ≥2 
postoperative complications than HIV-unspecified patients. Increased postoperative 
complications, in general, and postoperative pulmonary complications, in particular, were 
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associated with decreased pulmonary functional status [26, 27]. Although DLCO might 
be a relevant factor, we hesitate to make definitive conclusions due to few study patients 
with DLCO data. HIV-infected patients also showed increased progression to recurrence. 
This maybe important since it suggests a potential biologic mechanism of NSCLC 
progression involving immunosuppression [28]. 
The obvious limitation of 22 HIV-infected surgical patients is the lack of 
precision inherent in a small sample size precluding strong recommendations. The 
observed estimates of effect could simply be due to random variability. Second, it was 
uncommon to test for HIV antibodies during the initial work-up of the general NSCLC 
patient at our institution. It is plausible that at NSCLC diagnosis, some individuals with 
sub-clinical HIV-infection could have been misclassified. However, given the thorough 
nature of clinical assessments of cancer patients at this institution, the probability of 
missing an HIV-infected individual is low. Lastly, the treatment assignment of HIV 
infection status is a complex construct of many factors related to health and survival. 
Thus, the mechanism through which decreased survival is associated with HIV infection 
is not clearly understood within the context of this study. Notwithstanding, this study 
utilized a powerful design and analytic methods to improve statistical efficiency and 
balance between HIV-infected and HIV-unspecified patients. Unmeasured covariates that 
could account for the effect estimates observed would have to be strongly associated with 
HIV infection and survival. 
 
Conclusions 
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In summary, although surgical treatment remains the best option for localized disease, 
few HIV-infected NSCLC patients present with resectable disease. Despite HIV-infected 
patients having comparable 30-day mortality rates to HIV-unspecified patients, surgery is 
associated with more postoperative complications, more rapid progression to disease 
recurrence and poorer long-term survival rates. Rapid cancer recurrence and poor long-
term survival rates seem particularly evident in patients with chronically suppressed 
immune status, i.e. patients with CD4 counts <200 cells/mm3. Careful HIV-infected 
patient selection based on DLCO may improve post-operative complication rates and 
optimizing immune status prior to surgery may ameliorate long-term cancer survival 
rates, but due to the small sample size, no definitive recommendations can be made. 
Future investigations should consider pooled analytic designs as well as prospective 
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Table 4-1. Characteristics of NSCLC Patients who Underwent Surgery According to 
HIV-Infected and HIV-Unspecified Status. (N=2,452) 
 
HIV-Infected          
(n=22) 
 
HIV-Unspecified            
(n=2,430) 
 Characteristics # %   # % p value* 
Median age, years & IQR 47.5 42 - 55 
 
65 58 - 72 <0.001 
Gender 
     
0.019 
  Male 17 77.3 
 
1,266 52.1 




     
<0.001 
  White 8 36.4 
 
1,981 81.5 




     
0.355 
  Adenocarcinoma 9 40.9 
 
1,153 47.4 
   Squamous cell 8 36.4 
 
663 27.3 
   Large cell 3 13.6 
 
162 6.7 
   NSCLC, nos 2 9.1 
 
184 7.6 
   BAC 0 0.0 
 
232 9.6 




     
0.766 
   I 13 59.1 
 
1,278 52.6 
    II 3 13.6 
 
408 16.8 
    III 5 22.7 
 
456 18.8 
    IV 1 4.6 
 
288 11.8 
 Smoking status 
        Never 0 0.0 
 
275 11.3 0.163 
  Ever 22 100 
 
2,155 88.7 
 Mean Pack-Years Smoked,                      
years and ± S.D.** 42.6 18.5 
 
53.6 32.9 0.012 
Procedure 
     
0.677 
   Lobectomy 19 86.2 
 
1,830 75.3 
    Wedge resection 1 4.6 
 
265 10.9 
    Pneumonectomy 1 4.6 
 
136 5.6 
    Segmentectomy 0 0.0 
 
81 3.3 
    Bilobectomy 1 4.6 
 
44 1.8 




     
0.081 
   1 0 0.0 
 
5 0.2 
    2 0 0.0 
 
430 17.7 
    3 20 90.9 
 
1,829 75.3 
    4 2 9.1 
 
166 6.8 
    5 0 0.0 
 
0 0.0 
 30-Day Mortality 0 0.0 
 
57 2.3 0.991 
Median time from diagnosis to 
surgery, days & IQR  72 36 - 108   37 18 - 70 0.001 
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* χ2 test for homogeneity or Fisher's exact test for binary and categorical variables; nonparametric Mann-Whitney U test or 
Student's t-test for continuous variables. 
** Number of pack years smoked on 1,839/2,542 (75%) of patients.  
IQR, interquartile range; NSCLC, nos, non-small cell lung cancer, not otherwise specified; BAC, bronchioloalveolar 





Table 4-2. Crude and Multivariable Cox Regression Models of Long-term Survival for NSCLC Patients 
after Surgery. (N=2,452) 
  
Crude    
Hazard 
Ratio 95% CI p value 
Adjusted 
Hazard 
Ratio* 95% CI p value 
HIV infection status 
  
  
     HIV-Unspecified 1.00 referent   1.00 referent 
   HIV-Infected 2.24 (1.37 - 3.68) 0.001 3.08 (1.85 - 5.13) <0.001 
* Adjusted for HIV infection, age, sex, race, NSCLC histology, HAART era (<1996 vs. ≥1996), stage, surgical procedure, ASA 




Table 4-3a. Study Characteristics of a Matched Sub-Cohort of NSCLC Surgical Patients 
According to HIV-Infected and HIV-Unspecified Status. (N=88) 
 
HIV-Infected          (n=22) 
 
HIV-Unspecified†            
(n=66) 
 
Characteristics # %   # % p value* 
Median age, years & IQR 48 42 - 55 
 
52 46 - 58 0.175 
Sex 
     
1.00 
  Male 17 77.3 
 
51 77.3 




     
0.899 
  White 8 36.4 
 
25 37.9 
   Black 14 63.6 
 
41 62.1 
 Marital Status 
     
0.004 
  Not Married 18 81.8 
 
31 47.0 
   Married 4 18.2 
 
35 53.0 
 Median household income, 
dollar & IQR 28,945 24,223 - 31,971 
 
32,458 20,465 - 52,973 0.143 
Location of residence 
     
0.262 
  Outside Baltimore City 7 31.8 
 
30 45.5 
   Within Baltimore City  15 68.2 
 
36 54.5 
 Diagnosis by HAART era 
     
0.752 
  <1996 3 13.6 
 
12 18.2 




     
0.129 
  Adenocarcinoma 9 40.9 
 
30 45.5 
   Squamous cell 8 36.4 
 
20 30.3 
   Large cell 3 13.6 
 
1 1.5 
   BAC 0 0.0 
 
6 9.1 




     
0.989 
   I 13 59.1 
 
37 56.1 
    II 3 13.6 
 
11 16.7 
    III 5 22.7 
 
15 22.7 
    IV** 1 4.6 
 
3 4.5 
 Smoking Status 
     
0.330 
  Never 0 0.0 
 
6 9.1 
   Former 0 0.0 
 
12 18.2 
   Current 22 100 
 
48 72.7 
 Mean Pack-Years Smoked,       
years and ± S.D. 42.6 18.5 
 
45.3 24.7 0.606 
† HIV-unspecified patients were matched on age, sex, race, stage, NSCLC histology, date of surgery, and surgical procedure. 
* χ2 test for homogeneity or Fisher's exact test for binary and categorical variables and nonparametric Mann-Whitney U test or Student's t-test for 
continuous variables. 
** Metastatic site includes, HIV-infected: contralateral lesions with paratracheal nodal involvement (1). HIV-unspecified: solitary brain lesion (3). 





Table 4-3b. Treatment Characteristics of a Matched Sub-Cohort of NSCLC Surgical Patients According to HIV-
Infected and HIV-Unspecified Status. (N=88) 
 
HIV-Infected                    
(n=22) 
 
HIV-Unspecified†                         
(n=66) 
 Characteristics # %   # % p value* 
Surgical Procedure 
     
0.903 
   Lobectomy 19 86.2 
 
51 77.2 
    Puemonectomy 1 4.6 
 
6 9.1 
    Wedge resection 1 4.6 
 
4 6.1 
    Bilobectomy 1 4.6 
 
2 3.0 




     
0.101 
   2 0 0.0 
 
10 15.2 
    3 20 90.9 
 
53 80.3 
    4 2 9.1 
 
3 4.5 
 Median time from diagnosis to surgery, days & IQR  72 36 - 108 
 
40 15 – 91 0.020 
Median length of hospital stay, days and IQR 9 6 -12 
 
5 4 – 7 0.025 
Mean number of days until chest tube removal, days and 
± S.D 6 3.9 
 
4 2.7 0.068 
Neoadjuvant Therapy 
     
0.503 
  None 54 81.8 
 
20 90.9 
   Received 12 18.2 
 
2 9.1 
 Adjuvant Therapy 
     
0.367 
  None 41 62.1 
 
16 72.7 
   Received 25 37.9 
 
6 27.2 
 Pulmonary Function 
        Mean FVC % predicted, ± S.D  87.8 17.3 
 
82.8 18.3 0.314 
  Mean FEV1 % predicted, ± S.D 80.4 24.9 
 
72.9 19.9 0.262 
  Mean DLCO % predicted, ± S.D 69.1 20.6 
 
86.1 25.2 0.025 
Postoperative Complications§ 
        Pulmonary  13 59.1 
 
12 18.2 0.001 
  Cardiac 0 0.0 
 
3 4.5 0.570 
  Infectious 8 36.4 
 
3 4.5 <0.001 
  Neurologic 0 0.0 
 
2 3.0 0.899 
  Bleeding 4 18.2 
 
1 1.5 0.013 
  Other Complications 6 27.3 
 
2 3.0 0.003 
At least two postoperative complications  
     
<0.001 
  <2  12 54.5 
 
60 90.9 
   ≥2 10 45.5 
 
6 9.1 
 Mean number of days until first complication, days and ± 
S.D 3 2.4 
 
3 1.9 0.985 
30-Day Mortality  0 0.0 
 
1 1.5 0.994 
Cause of Death 
     
0.361 
  Lung cancer-related 11 61.1 
 
27 60.0 
   AIDS-related 1 5.6 
 
0 0.0 
   Other Causes‡ 4 22.2 
 
15 33.3 
   Cause Unknown 2 11.1 
 
3 6.7 
 † HIV-unspecified patients were matched on age, sex, race, stage, NSCLC histology, surgery date, and surgical procedure. 
* χ2 test for homogeneity or Fisher's exact test for binary and categorical variables and Mann-Whitney U test or Student's t-test for continuous variables. 
§ Postoperative complications include, Pulmonary: air leak (13), atelectasis (6), pneumothroax (7), pleural effusion (7), pulmonary embolus (3), ARDS (1), respiratory failure (1), 
hypoxia (1); Cardiac: dysrhythmia (2), myocaridal infarct (1); Infectious: pneumonia (4), fever (4), wound infection (4), bronchiopleural fistula (1), chest infection (1); Neurologic: 
mental status change (2); Bleeding: thoracic wall hemotoma (1), tracheostomy bleeding (1), persistent hemoptysis (1), chest hemorrage (1); Other complications: acute renal failure 
(2), reintubation (2), blood clot (1), ileus (1), uncontrolled pain (1), secondary cancer diagnosis (1). Note- some patients had multiple postoperative complications within a broader 
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categories listed in the table above.  
‡ Other causes of death include, HIV-infected: bleeding from tracheostomy (oropharyngeal cancer) (1), congestive heart failure/atherosclerotic CVD(1), respiratory failure septic 
shock ascending cholangitis hepatic artery injury PEA arrest (1), multisystem organ failure following cardiac surgery (1). HIV-unspecified: CVD/ myocardial infarction (5), 
pulmonary arrest (2), pneumonia (1), diabetic complication (1), arteriovenous malformation complications (1), pyriform sinus cancer (1), multiple myeloma (1), esophageal cancer 
(1), breast cancer (1), head and neck cancer (1). 
IQR, interquartile range; S.D., standard deviation; ASA, American Society of Anesthesiology Classification morbidity index; FVC, forced vital capacity; FEV1, forced expiratory 







Table 4-4. Crude and Multivariable Cox Regression Models of Long-term Survival for NSCLC 
Patients after Surgery in a Matched Sub-Cohort. (N=88) 
  
Crude    
Hazard 
Ratio 95% CI p value 
Adjusted 
Hazard 
Ratio* 95% CI p value 
HIV infection status 
  
  
     HIV-Unspecified  1.00 referent   1.00 referent 





     < 2 1.00 referent   1.00 referent 
   ≥ 2 2.01 (1.03 - 3.92) 0.040 3.85 (1.39 - 10.68) 0.009 
* Adjusted for HIV infection, age, sex, race, marital status, Baltimore City residence, median household income, HAART era 
(<1996 vs. ≥1996), NSCLC histology, stage, surgical procedure, ASA classification, hospital stay, post-operative 


























Figure 1. Kaplan-Meier All-Cause Survival Following Surgical Resection 
Comparing Non-Small Cell Lung Cancer tatients by HIV Infection Status (N=2,452)
No. at Risk (% survived)
HIV − 2,430 (100)               1,964 (84)                   1,493 (69)                    1,198 (60)                     931 (50) 761 (44) 
HIV + 22 (100)                     13 (67)                           9 (51)                            6 (34)               3 (17)                       2 (17)                                            
Key                HIV Status                      Median (mths)
HIV-unspecified                    48.4     





























No. at Risk (% survived)
≥200 16 (100)                        11 (81)                          9 (73)                            6 (65)                3 (43)                          2 (43) 
<200         6 (100)                          2 (40)                             0 (0)                             0 (0)                  0 (0)                            0 (0)                                            
Figure 2. Kaplan-Meier Cancer-Specific Survival of 
HIV-Infected Non-Small Cell Lung Cancer tatients who Underwent Surgical Resection 
According to CD4 Cell Count (cells/mm3) ≥200 vs. <200 (N=22)
Log-rank p=0.031
Key                  CD4 Cell Count       Median (mths)                
≥ 200 cells/mm3 40.0  
































Figure 3. Cumulative trobability of Cancer trogression Following Surgical Resection 
Comparing Non-Small Cell Lung Cancer tatients 
by HIV Infection Status (N=84*)
Key              HIV Status                Median (mths)
HIV-infected                        20.4
HIV-unspecified                  NYR                      
No. at Risk (% progressed)
HIV + 21 (0)                         10 (44)                         7 (51)                           4 (58)                3 (58)                          2 (58)                                                                 
HIV − 63 (0)                         42 (25)                       29 (39)                        23 (44)                   20 (46)                        16 (49)
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Synthesis of evidence 
The primary objective of this research was to utilize epidemiologic methodologies to 
identify factors associated with optimal surgical management and examine postoperative 
outcomes in surgical patients with thoracic cancers within a single hospital setting. We 
investigated three separate patient populations with distinct but equally important issues 
related to survival within a clinical setting where surgery was the definitive therapeutic 
option: 1) locally advanced esophageal cancer patients who received combined 
neoadjuvant chemoradiation therapy followed by surgery, 2) patients diagnosed with 
early stage non-small cell lung cancer, and finally 3) HIV-infected patients diagnosed 
with non-small cell lung cancer. These issues have important implications for future 
clinical and public health research and impact how decisions are made with respect to 
treatment and overall survival among patients with thoracic cancer. The three aims and 
related results are described here. 
 
Aim 1. To assess the long-term postoperative survival of patients with locally advanced 
esophageal adenocarcinoma treated with combined chemoradiation followed by surgery 
and adjuvant chemotherapy.  
 Although current clinical guidelines are becoming more refined results stemming 
from recent randomized clinical trials with respect to best treatment practices for 
neoadjuvant chemoradiation and surgery for patient diagnosed with locoregional 
esophageal cancer, the long-term survival risks and benefits of adjuvant chemotherapy 
remains unclear. To this point, clinical decision to provide adjuvant chemotherapy is 
made on a case-by-case basis. The only clinically-based indicator for predicting long-
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term survival of patients with locally advanced esophageal cancer is pathological 
response to neoadjuvant chemoradiation followed by surgery. A pathological complete 
response confers the best long-term survival for patients with 5-year postoperative overall 
survival ranging from 50% to 80% compared with pathological partial- and no-response 
about (35% and 20%, respectively) [1]. 
 We hypothesized that patients diagnosed with locally advanced esophageal 
adenocarcinoma who received adjuvant chemotherapy would have improved survival 
compared to patients with similar clinicopathologic characteristics and pathologic 
response who received combined chemoradiation followed by surgery alone treated at 
Johns Hopkins Hospital from 1989 to 2011. In this single-institution, retrospective cohort 
study spanning more than 20 years, we found that patients who received adjuvant 
chemotherapy had a decrease in relative hazards for postoperative mortality compared to 
patients who did not receive adjuvant chemotherapy, after adjusting for age, ASA 
performance status, and pathologic complete response. In addition, when stratified by 
pathologic response, partial responders were found to have the most survival benefit from 
adjuvant chemotherapy with longer median survival vs. partial responders that received 
multimodality therapy alone. Our data suggest that when a neoadjuvant chemotherapy 
regimen that induces a significant pathologic response, more of that same chemotherapy 
given adjuvantly may increase survival benefit. Conversely, if the neoadjuvant 
chemotherapy regimen does not provoke a significant pathologic response, changing the 
adjuvant therapy to a different chemotherapeutic regimen may improve survival among 
pathologic partial responders.  
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 Results from this study may aid clinicians in deciding whether patients with 
pathologic complete, partial, or no response to multimodality therapy should continue 
treatment with adjuvant chemotherapy. Finally, this study marks the initial movement 
toward a better understanding of a continuum of therapy for locally advanced esophageal 
cancer patients from neoadjuvant chemoradiation to surgery and potentially to subsequent 
adjuvant chemotherapy. It is our hope that findings from this study will serve as a basis 
of constructive dialogue for which to improve upon methodology and scope for future 
large-scale prospective studies leading to more definitive randomized control trials.             
 
Aim 2. To examine differences by race on recommendation for surgical therapy and 
postoperative survival among early stage non-small cell lung cancer patients. 
 Given the striking difference in survival between patients with early stage non-
small cell lung cancer who undergo surgical resection and those who have alternative 
treatment, it is not surprising that research has shown that much of the higher mortality in 
blacks with early stage NSCLC can be attributed to lower surgical rates compared with 
whites [2]. However, it has been difficult to directly assess the underlying reason for this 
disparity in surgical rates. To better understand the factors influencing the 
recommendation for surgery, we conducted a retrospective cohort study with early stage 
NSCLC patients treated at Johns Hopkins Hospital from 2000 to 2010.  
 We hypothesized that there would be no racial disparities among patients with 
early-stage non-small cell lung cancer patients who received a recommendation for 
surgery at Johns Hopkins Hospital between 2000 and 2010. We further hypothesized that 
overall survival would not differ by race once surgical recommendation was taken into 
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account. Results for this study showed that black patients were recommended for surgery 
8% less than white patients, but after accounting for patient-, tumor-, and physician-
related factors no association existed by race. Race as a risk factor alone was not 
independently associated with surgical recommendation or overall survival. Our findings 
suggest that patient-, tumor-, and physician-related factors have a greater influence in the 
treatment recommendation decision process than race alone. Access to care with respect 
to consultation for surgical treatment did not differ by race. Furthermore, among patients 
whose initial physician encounter was with a non-surgeon, if the recommendation was 
not to have surgery a surgeon consequently corroborated the recommendation equally by 
race.  
 
Aim 3. To determine the effect of HIV infection on post-surgical outcomes among non-
small cell lung cancer patients. 
 At present, the general consensus based on limited information the 
recommendations for surgical intervention for HIV-infected individuals remain similar to 
general lung cancer population, namely surgical resection for curative intent in HIV-
infected patients with localized disease and good performance status [3]. We 
hypothesized that HIV-infected patients with NSCLC would have poorer postoperative 
survival compared to HIV-unspecified NSCLC patients with similar clinical risk factors 
who underwent surgery at Johns Hopkins Hospital from 1985 to 2009. We further 
hypothesized that HIV-infected patients would have shorter time to disease progression 
as compared to HIV-unspecified patients with similar clinical risk factors following 
surgery with curative intent. 
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 The analysis in this study compared HIV-infected NSCLC surgical patients to all 
HIV-unspecified NSCLC patients that received surgery during the same time period 
(unmatched) and then a 3:1 individual matched sub-group analysis to examine more 
detailed surgical characteristics. Results from both analyses conferred dismal prognosis 
for HIV-infected NSCLC patients. Compared to HIV-unspecified NSCLC patients, 
postoperative overall survival and progression-free survival was significantly shorter in 
HIV-infected NSCLC patients. Even after matching on major clinical prognostic factors, 
HIV-infected patients exhibited a greater relative hazard for mortality. Within the HIV-
infected NSCLC group, patients with a CD4 count ≤200 cells/mm3 at time of surgery had 
significantly poorer survival. Additionally, following surgery, HIV-infected NSCLC 
patients developed more postoperative complications and showed more rapid progression 
to metastatic disease or recurrence compared to HIV-unspecified NSCLC patients.  
 Although surgical treatment remains the best option for localized NSCLC, results 
from this study suggest HIV-infected NSCLC have poorer survival and disease-free 
survival after surgery as compared to the general lung cancer population. These 
observations may be explained in part by inadequate recovery after surgery and more 
aggressive disease progression due to chronic immunosuppression or more aggressive 
tumor biology. Clinical decisions for surgical management among HIV-infected patients 
diagnosed with NSCLC should consider the patient’s overall health status and encourage 





This research contributes important information for medical decision-making between 
clinicians and patients considering best surgical management practices for patients with 
esophageal and lung cancer. First, we found in esophageal adenocarcinoma patients, 
specifically pathologic partial responders, that adjuvant therapy can provide improved 
postoperative survival. Furthermore, patients that had a significant clinical response to a 
specific neoadjuvant chemotherapy regimen and continued to receive the same adjuvant 
chemotherapy regimen had better median postoperative survival compared to patients 
that received a different adjuvant chemotherapy regimen. The two most frequently 
administered classes of chemotherapy are platinum- and taxane-based chemotherapies. 
There are no clinical or molecular markers to help guide clinicians decisions on how to 
predict patient response to a specific neoadjuvant chemotherapeutic regimen. Although 
patients in our study were not explicitly randomized to a particular neoadjuvant 
chemotherapy regimen, results from our study may help to reinforce clinical decisions on 
adjuvant chemotherapeutic regimens.    
 
Public health significance 
Several areas of research stemming from these studies have important implications 
beyond the clinical setting.  Mainly, race and ethnic disparities in the receipt of treatment 
for lung cancer is an important public health concern. Racial and ethnic minority and 
white patients who receive similar care for the same stage of disease have been shown to 
have similar survival for lung cancer, irrespective of socioeconomic status [4, 5]. New 
data on CT screening for lung cancer suggest a 20% reduction in mortality for persons at 
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high risk [6]. In fact, the 2013 American College of Chest Physicians (ACCP) Lung 
Cancer Guidelines (LC III) suggests, “3.4.1. For smokers and former smokers who are 
age 55 to 74 and who have smoked for 30 pack-years or more and either continue to 
smoke or have quit within the past 15 years, we suggest that annual screening with low-
dose CT (LDCT) should be offered over both annual screening with CXR or no 
screening, but only in settings that can deliver the comprehensive care provided to 
National Lung Screening Trial participants (Grade 2B).” [7].  
 Early diagnosis of lung cancer provides the best chance for optimal treatment for 
cure. Results from our study support the conclusion that surgery at early stage provides 
equal opportunity for improved overall survival, irrespective of race and socioeconomic 
status. Public health interventions that emphasize improved access to CT screening for 
lung cancer and subsequent early treatment across race and socioeconomic status will 
likely play a critical role in the reduction of lung cancer deaths. Finally, these studies add 
to the evidence base for future research on surgical management and postoperative 
outcomes for patients with thoracic cancer.     
 
Future research directions 
Findings from this research suggest several future lines of investigation. Currently, 
clinicians still rely on histopathological examination of the resected specimen to 
determine the degree of pathologic response to neoadjuvant therapy. Our research group 
has begun investigating markers to predict pathological response to neoadjuvant therapy. 
As we have found, patients undergoing neoadjuvant therapy who are deemed non-
responders fared worse in survival, stage for stage, than all other treatment groups. 
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Identifying this subgroup of patients with esophageal cancer would potentially avoid 
neoadjuvant therapy in about 20% of patients who would not benefit from such an 
approach. This would allow for surgical treatment or potential alternative regimens to be 
initiated earlier. Genetic analysis of esophageal cancer and its histological sub-types, 
adenocarcinoma and squamous cell carcinoma, may offer a new strategy of improved 
outcomes through detection of molecular biomarkers. Prognostic stratification of patients 
will promote the development of new targeted therapies leading to better response rates 
and lower treatment-related morbidity. 
 A particularly promising novel biomarker is emerging as a predictor to taxane-
based chemotherapy [8]. Checkpoint with FHA and ring finger domains (CHFR) is a 
mitotic checkpoint- and tumor suppressor gene and is inactivated in a diverse number of 
solid malignancies [8]. CHFR inactivation has been identified in studies as a prognostic 
marker for reduced outcomes for NSCLC [9, 10] and colorectal cancer [11]. CHFR also 
has been identified as a predictive marker to increased sensitivity to taxane-based 
chemotherapeutic agents for NSCLC [12, 13], gastric [14], cervical [15], and endometrial 
cancers [16]. Taxane-based chemotherapeutic agents, along with platinum-based 
chemotherapies, are mainstay treatments for both NSCLC [17] and esophageal cancer 
[18] .  
 Our research group is currently enrolling locally advanced esophageal 
adenocarcinoma patients into a phase II trial at the Sidney Kimmel Comprehensive 
Cancer Center at Johns Hopkins investigating CHFR methlyation status on pathologic 
response to neoadjuvant chemotherapy and radiation comparing taxane- and platinum-
based regimens (paclitaxel and cisplatin, respectively) compared to platinum-based 
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regimens alone followed by surgery [19]. The objective of this study is to determine the 
rate of pathological complete response when the inclusion of paclitaxel chemotherapy 
regimen in neoadjuvant therapy is based on the presence or absence of CHFR 
methylation in diagnostic biopsy specimens. While this is not a randomized clinical trial, 
we hope to gain further knowledge on how molecular biomarker analysis can help to 
inform clinicians on better treatment options for esophageal cancer patients.      
 We found that access to surgery, at our institution, did not differ between black 
and white patients with early stage NSCLC. Health disparities research on treatment for 
lung cancer remains complex and evidence demonstrates that no one factor can be fully 
attributed to treatment inequalities. The complex interaction between race, 
socioeconomic status, and other socio-cultural mechanisms may overshadow more 
proximal determinants of treatment. Perhaps we should try to better understand and 
appreciate the influence of more specific social or economically influenced barriers to 
cancer treatment, such as availability for care, (i.e., the ability to take time off work, lack 
of support for child/spousal care), transportation to medical appointments, support 
systems, and attitudes and understanding of disease severity. Studies that can examine 
more personal influenced barriers to cancer treatment may prove more informative for the 
development of interventions designed to reduce health disparities. 
 Studies have shown that age-adjusted incidence of lung cancer is greater among 
HIV-infected individuals compared to the general lung cancer population [20, 21]. It is 
unclear whether the elevated increase in risk for lung cancer among HIV-infected patients 
is due to excessive cigarette smoking prevalence or factors directly related to the HIV 
disease and/or its associated co-morbidities and treatment. Regardless of the risk factors, 
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lung cancer has become a leading cause of death among HIV-infected persons [22]. The 
majority of HIV-infected patients are diagnosed with advanced stage lung cancer, when 
palliative chemotherapy and radiation therapy are the only available treatment options 
however there is a paucity of data on the treatment effects and chemo- and radiation- 
toxicity of systemic therapy in this population.  
 An important bioethical debate with public health policy implications has focused 
on the exclusion of HIV-infected persons from cancer clinical trials. A review of the 
NCI’s Physician Data Query (PDQ) clinical trial database revealed that approximately 
25% (95 of 383) phase I, II, and III treatment trials for non-small cell lung cancer 
explicitly exclude HIV infection [23]. Problems with excluding HIV-infected individuals 
from cancer clinical and screening trials can limit the representativeness of the study 
sample, thus reducing generalizability, and potentially limit the evidence base for cancer 
therapy. Improvements in HIV treatment and survival have consequently allowed for 
advances in treatment of certain AIDS-defining cancers, which have resulted in outcomes 
equivalent to those seen in similar cancers in the HIV-seronegative population [24]. 
Future trial designs must place emphasis on fair evaluation of cancer patients with HIV 
infection for reasonable and safe access to cancer clinical trials and potentially clinically 
promising therapies. 
 The National Lung Cancer CT screening Trial (NLST) reported a 20% reduction 
in mortality associated with annual computed tomography (CT) screening for older, 
heavy smokers at high risk for lung cancer [6]. Given that the majority of HIV-associated 
lung cancers are diagnosed at late stage, CT screening may have profound implications 
for improving earlier diagnosis of this high-risk group. There are no data, however, to 
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support routine lung cancer screening in HIV-infected smokers because most CT 
screening studies, including the NLST, excluded their enrollment. For the same reasons 
as cancer clinical trials, fair recruitment into future CT screening trials should be 
considered for HIV-infected smokers at high risk for lung cancer.  
 
Conclusions 
This dissertation used clinical epidemiological methodologies to examine outcomes 
associated with optimal surgical management for lung and esophageal cancer patients 
treated at Johns Hopkins Hospital. We have found that adjuvant chemotherapy was 
associated with a reduction in mortality for esophageal adenocarcinoma patients after 
neoadjuvant chemoradiation followed by surgery. Pathologic partial responders have the 
most benefit to adjuvant chemotherapy compared to pathologic complete and non-
responders. Future research on molecular biomarkers that can predict pathologic response 
to neoadjuvant therapy will help improve clinical decisions, reduce potential harm due to 
unnecessary additional therapy, and advance research for individualized therapies.  
 We contributed to the body of evidence on racial and ethnic disparities in surgical 
treatment patients diagnosed with early stage NSCLC. Conclusions from our 
investigation on race disparities in surgical recommendation suggest that race alone was 
not an independent risk factor for surgical recommendation or survival after accounting 
for patient-, tumor-, and physician-related factors. Racial disparities in surgical resection 
rates might be explained, in part, by social and economic conditions specific to the 
patient. On a clinical level, future research designs should focus on patient-level factors 
for example, time off work to undergo treatment, lack of social and spousal support, need 
124 
 
to care for another family sick member, transportation to medical visits, and awareness of 
disease severity. Information about specific patient-level factors that can help clinicians 
identify candidates for surgery with curative intent at high risk for refusing surgery 
realistically can only be accomplished within a clinical setting. Nevertheless, public 
health efforts must continue to improve minority inclusion into CT screening, clinical 
trials, and primary prevention programs on a population level.  
 Finally, we observed HIV-infected NSCLC patients to be associated with shorter 
postoperative survival compared to HIV-unspecified NSCLC patients with similar 
clinical characteristics. Surgical resection remains the best treatment for cure for NSCLC 
however HIV-infected NSCLC patients have more postoperative complications and rapid 
progression of disease after surgery. Clinicians should consider the overall health status 
and immune function of NSCLC patients with HIV infection before surgery and also 
consider adjuvant chemotherapy with extra vigilance following surgery.  
 Future research is necessary to further understand the relationships studied in each 
aim of this dissertation. Furthermore, efforts need to be made by both the medical and 
public health community to promote the policy, prevention, early detection, and treatment 
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2003 “Are Multiple Tumors in Lung Cancer Patients Primarily Due to Tobacco?”  
 American Association of Cancer Research 
 Washington, DC 
 
 “Risk of Subsequent Primary Neoplasms Developing in Lung Cancer Patients 
with Prior Malignancies.” 
American Association for Thoracic Surgery  
 Boston, MA 
 
  “Pulmonary Resection in the Octogenarian with Stage I Non-Small Cell Lung 
Cancer (NSCLC): A 22 Year Experience.”  
 Society of Thoracic Surgeons 
 San Diego, CA 
 
 “Prognostic Value of hMLH1 Hypermethylation and Microsatellite Instability in 
Surgically Resected Endocrine Tumors of the Pancreas.” 
 American Association of Endocrine Surgeons 
 San Diego, CA 
 
 “Tumor Suppressor Gene Hypermethylation as a Predictor of Gastric Stromal 
Tumor Behavior.” 
 Society of Surgery of the Alimentary Tract, Digestive Disease Week 
 Orlando, FL 
 






 Molecular Cancer Therapeutics, 2013 – present  






2011 Graduate Teaching Assistant 
 Epidemiologic Methods, Section I of IV 
 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health 
2010 Graduate Teaching Assistant 
 Epidemiologic Methods, Section II of IV 









 Benjamin Cooper; JHU, Honors thesis advisor 
 Hayley Osen; JHU, Honors thesis advisoru 
 Johnathon Taylor; JHU, Honors thesis advisor 
 Nicholas Theodosakis, UVA, Honors thesis advisor 
 Aliyah Sanders; JHU, Honors thesis advisor 
 
Medical Students: 
 Florence Wu; JHU, 2007 AATS Surgical Fellowship recipient, mentor 
Nan Zhu; JHU, 2008 AATS Surgical Fellowship recipient, mentor 
 Joshua Taylor; JHU, Surgical research, advisor 
 Helen Selonick-Prevas, JHU, Medical oncology research, advisor 
 Yelena Prints; JHU, Medical oncology research, advisor 
 Joani Christensen; JHU, Medical oncology research, advisor 
 Nance Yuan; JHU, Medical oncology research, advisor 
 Solange Cox; JHU, Surgical research, advisor 
 Jennifer Zhang; JHU, 2010 AATS Surgical Fellowship recipient, mentor 
 George Yufei Tang; JHU, 2011 AATS Surgical Fellowship recipient, mentor 
 Kanika Trehan; JHU, Surgical research, advisor 
 Vernissia Tam; JHU, Surgical research, advisor 
 Malcolm Stennet; Howard University, 2013 AATS Surgical Fellowship recipient, 
 mentor  
 Tim Xu; JHU, Surgical research, advisor 
 Sneha Shah; JHU, Surgical research, advisor 
 Jessica Moore; JHU, 2014 AATS Surgical Fellowship recipient, mentor 
 
Medical/Surgical Fellows: 
 Alicia Hulbert, M.D.; JHU, general clinical outcomes research 
 Luckson Mathieu, M.D.; JHU, general clinical outcomes and epidemiology 
 research  
 John Wrangle, M.D., M.P.H; JHU, general clinical outcomes research 
 Mario Teran, M.D.; JHU, surgical outcomes research 
  
Honors and Awards: 
 
2009 Harvey M. Meyerhoff Fellowship in Cancer Prevention 
 The Johns Hopkins Bloomberg School of Public Health 
2004 The Edward A. Smuckler Memorial Workshop: Pathobiology of Cancer 
Scholarship  Educational Workshop 
 American Association For Cancer Research  
2002 Trish Greene Quality of Life Award 






American Association for Cancer Research 
 Associate member, July 2004 - Present  
Society of Thoracic Surgeons 
 Associate member, June 2013 - Present  




2011 CITI- Human Subjects Research Ethics Certification  
 Johns Hopkins Bloomberg School of Public Health 
2003 HIPAA Compliance Training Certification 
The Johns Hopkins University School of Medicine  
1999 Human Subjects Research Compliance Certification 




Proficient in the following statistical packages: 
- STATA, R, SAS 
